ARCH Venture Partners
Arch Venture Partners, L.P. is a private equity and venture capital firm specializing in investments in growth capital and development of seed and early-stage technology companies. It invests conservatively at first in a seed round to reduce or extinguish risk and then leads or co-leads additional rounds of financing all the way to liquidity. It seeks to invest in disruptive technologies worldwide. It primarily invests with focus on life sciences, biotechnology, chemicals and specialty materials, advanced materials, specialty semiconductors, consumer electronics, instrumentation, physical sciences, communications technologies, electronics, software/applications, Nanotechnology, alternative energy, retailing, e-commerce software, b2b commerce, enterprise information portals, knowledge management software , convergence technology, and information technology. Within technology, it invests in clean technology innovations, optics and photonics, electronic components, network infrastructure and security, high performance computing, wireless communications, pharmaceuticals, genomics and bioinformatics, medical devices, diagnostic and drug discovery platforms; nano- and microtechnologies. It maintains its presence in geographical areas that are typically underserved by seed investors but contain great centers of basic research and an active community of technologists. It maintains a national scope with a regional focus in geographic markets underserved by venture community. Within the healthcare sector, the fund focuses on companies working on neurodegenerative diseases, including Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis and also invests in companies addressing mental health needs around cognition, depression, schizophrenia and autism. It invests primarily in the United States but also in countries where the company has extensive scientific and business relationships, including Canada, Ireland, Iceland, South Korea, China, and Japan. It also seeks to invest in Europe. The firm typically invests between $50,000 and $150 million per company. The firm seeks a seat on the Board of Directors. Arch Venture Partners, L.P. was founded in 1986 and is based in Chicago, Illinois with additional offices across North America and South America.
Region
Sector
1700 Owens St., Suite 535 San Francisco, CA 94158
399 past transactions
Siluria Technologies Inc.
Series C in 2013
Siluria Technologies is a materials innovation company solving global challenges for partners in the natural gas, chemicals and fuel industries. Integrating nanotechnology, biotechnology and chemical engineering, Siluria has developed a solution to the grand challenge of efficient manufacturing: the ability to produce chemicals and fuels from a cheaper, more abundant resource than oil. The company's economically superior, energy-efficient platform converts natural gas into the same materials manufactured today using current industry infrastructure. Siluria's world-class R&D and engineering teams are rapidly commercializing the company's technology to pilot-scale production in close dialogue with the world's largest chemical and fuel companies.Siluria's backers include Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.
NeurogesX
Series A in 2000
NeurogesX, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel non-opioid, pain management therapies to address unmet medical needs. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is based in San Mateo, California.
ImmusanT
Series C in 2017
ImmusanT, Inc., a biotechnology company, develops therapies and personalized diagnostics to treat patients with celiac disease. The company focusses on disease-modifying approach to induce immune tolerance in autoimmune diseases. It offers Nexvax2, a therapeutic vaccine for celiac disease; and a diagnostic and monitoring tool to improve celiac disease management. ImmusanT, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.
Aledade
Series B in 2017
Aledade, Inc. provides services to primary care physicians to form and operate accountable care organizations (ACO) in the United States. It offers primary care providers access to data analytics, user-friendly guided workflows, regulatory expertise, payer relationships, and local support from attentive experts. The company also provides 360° practice support, workflow optimization, ACO governance, policy expertise, and contracting support services. It serves small practices, large practices, FQHCS/community health centers, and multispecialty groups. Aledade, Inc. was incorporated in 2014 and is based in Bethesda, Maryland.
Cambrios Technologies Corporation
Series C in 2007
Cambrios Technologies Corp. develops electronic materials for the display industry. The company provides wet-processable transparent conductive films. Its nanostructured materials can be deposited using existing production equipment to achieve enhanced performance of display devices and components. The company was founded in 2002 as Semzyme, Inc. and changed its name to Cambrios Technologies Corp. in August 2004. Cambrios Technologies Corp. is based in Sunnyvale, California.
Quanterix
Series C in 2012
Quanterix Corporation is developing a novel platform for single molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. Their unique approach permits rapid quantification and analysis of individual proteins and small molecules within complex biological samples, enabling us to address a variety of unmet medical needs. Founded in 2007, Quanterix is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures.
Denali Therapeutics Inc.
Series B in 2016
Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.
Sapphire Energy, Inc.
Venture Round in 2008
Sapphire Energy, Inc., a venture capital backed company, produces renewable solutions from algae. It uses sunlight, CO2, non-potable water, non-arable land, nutrients, and novel strains of algae in outdoor ponds to produce biomass that can then be converted into high-value oils, aquaculture and animal feeds, fuels, and other valuable products. The company was founded in 2007 and is based in San Diego, California. It has a research and development facility in Las Cruces, New Mexico; and an integrated algal bio refinery in Columbus, New Mexico.
Sapphire Energy, Inc.
Series A in 2007
Sapphire Energy, Inc., a venture capital backed company, produces renewable solutions from algae. It uses sunlight, CO2, non-potable water, non-arable land, nutrients, and novel strains of algae in outdoor ponds to produce biomass that can then be converted into high-value oils, aquaculture and animal feeds, fuels, and other valuable products. The company was founded in 2007 and is based in San Diego, California. It has a research and development facility in Las Cruces, New Mexico; and an integrated algal bio refinery in Columbus, New Mexico.
Aspen Neuroscience
Seed Round in 2019
Aspen Neuroscience, Inc. develops induced pluripotent stem cells to treat neurological conditions. Its products pipeline includes ANPD001, an autologous neuron replacement therapy in sporadic Parkinson disease; and ANPD002, a gene-edited autologous neuron replacement therapy for familial forms of Parkinson disease. The company was incorporated in 2018 and is based in San Diego, California.
Treeline Biosciences
Series A in 2021
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions.
The company was founded in 2021 and is headquartered in Stamford, CT.
One BioMed
Series A in 2019
One Biomed Pte. Ltd. provides integrated molecular diagnostics services. The company was incorporated in 2015 and is based in Singapore.
Extreme Devices
Venture Round in 2000
Extreme Devices is a manufacturer of semiconductor electronic components.
Boragen
Series A in 2017
Boragen develops synthetic chemistry platforms designed to produce next-generation fungicides. The platform supports sustainable farming methods by creating a compound that decreases the probability of fungicide resistance and reduces the amount of chemical applied while maintaining performance and efficacy. The company utilizes boron’s unique properties to design and develop novel solutions targeting needs in crop protection, animal health, and human health.
Founded in 2015, Boragen is based in Durham, North Carolina.
Xtera
Venture Round in 2003
Xtera Communications, Inc. is in the process of liquidation. Previously, it provided Raman amplification enabled optical transport systems for terrestrial and submarine networks worldwide. The company was founded in 1998 and is headquartered in Allen, Texas. On February 21, 2017, the voluntary petition of Xtera Communications, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on November 15, 2016.
Volastra Therapeutics, Inc.
Seed Round in 2020
Volastra Therapeutics, Inc., a biotechnology company, develops therapies for the treatment of metastatic cancers. The company offers a library of organoids derived from metastatic cancer samples to elucidate how tumors spread and devise therapeutic strategies that target chromosomal instability during the process of cancer metastasis. Volastra Therapeutics, Inc. was incorporated in 2019 and is based in New York, New York.
Agrivida, Inc.
Venture Round in 2019
Agrivida, Inc., an animal health and nutrition company, develops feed additives for poultry, swine, dairy and beef cattle, and aquaculture markets. The company offers nutrition solutions for monogastric and ruminant animals, and aquaculture. It offer GRAINZYME, a phytase feed additive for poultry sector. It also provides INzyme Enzymes that deliver regulated enzymes for detergents, oil and gas production, and food applications; and INzyme sugar feedstock advanced bio-based chemical and fuel production. Agrivida, Inc. was founded in 2003 and is based in Four Seasons, Missouri.
Twist Bioscience Corporation
Series A in 2014
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Locana
Series B in 2020
Locanabio, Inc., is an RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.
AgBiome, LLC
Series C in 2018
AgBiome, LLC, a biotechnology company, engages in delivering research and discovery to the agriculture industry. The company develops biological product that controls the predominant soil-borne diseases of greenhouse and major row crops. It identifies plant-associated microbes that enhance plant health, pest resistance, and yield applying based on genomics and screening technologies. AgBiome, LLC has strategic partnerships with Genective and ElevateBio. The company was incorporated in 2012 and is based in Durham, North Carolina.
MedVantx, Inc.
Series C in 2003
Headquartered in San Diego, California, MedVantx is an innovative consumer medication management and delivery company committed to reducing costs and providing information to benefit patients, healthcare providers, payors, employers and manufacturers.
Their state-of-the-art mail order pharmacy, operating in Sioux Falls, South Dakota, is licensed in all 50 states and serves as a full line mail order prescription drug and information provider to consumers. Their 35,000 square foot facility recently underwent major upgrades and now meets over 200 cGMP-level quality standards and can properly handle all pharmaceuticals requiring Cold Chain processing.
The MedStart Connect program is operational in a number of states including Arizona, California, Florida, Georgia, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island and South Carolina, and serves approximately 4,000 top-decile primary care prescribers. They continue to expand in additional states.
MedVantx was recognized by Inc. Magazine in 2009 as the fastest growing privately held healthcare company in the country and 13th fastest overall.
CStone Pharmaceuticals
Series B in 2018
CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative tumor immunotherapy and precision treatment drugs to meet the intensive medical needs of cancer patients in China and around the world.CStone Pharmaceuticals has assembled a world-class management team with extensive experience in new drug development, clinical research, and commercialization. The company has built a rich product pipeline composed of 15 tumor candidate drugs with the combination of tumor immunotherapy as the core.
Slingshot Biosciences, Inc.
Series A in 2021
Slingshot Biosciences aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs. Our technology platform will make a significant bottom-line impact on the speed and cost of early-stage discovery, research and development programs.
National Resilience, Inc.
Series B in 2020
National Resilience, Inc., doing business as Resilience, operates as a biopharmaceutical manufacturing and technology company that provides end-to-end manufacturing and development solutions. It focuses on investing in developing new manufacturing technologies across various therapeutic modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. The company was incorporated in 2020 and is based in La Jolla, California.
Mindstrong Inc.
Series C in 2020
Mindstrong Health develops comprehensive care pathways based on passively-collected, continuous and objective measures of cognitive function and mood. Solutions include a patient-facing app, a provider-facing product, and clinical services that leverage its telehealth enabled measurement science and engagement platform. Mindstrong is partnered with leading organizations committed to advancing medical innovation and improving healthcare delivery for patients, including pharmaceutical companies, large payers and providers, large employers, and state and county governments, in addition to top-tier academic institutions for clinical research.
Surface Logix
Venture Round in 2005
Surface Logix is a drug development company which uses its expertise in biophysical chemistry to create new small molecule drugs with significantly improved pharmacokinetic (PK) and pharmacodynamic (PD) properties compared with class leaders.
Ceptyr
Venture Round in 1999
Ceptyr, Inc was founded to focus on developing drugs against protein tyrosine phosphatases (PTPs), a largely unexplored niche in pharmaceutical development.
Erasca
Series A in 2019
Erasca develops oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations, providing patients with new potential solutions to not just treat but cure cancer.
It was founded in 2018 and headquartered in San Diego, California.
Slingshot Biosciences, Inc.
Series A in 2023
Slingshot Biosciences aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs. Our technology platform will make a significant bottom-line impact on the speed and cost of early-stage discovery, research and development programs.
Transcenta Holding Ltd.
Post in 2021
Transcenta Holding Ltd., a biotherapeutics company, engages in the research and development and manufacturing of antibody-based therapeutics. The company also offers clinical researches and trial services. Transcenta Holding Ltd. was founded in 2019 and is based in Suzhou, China. It has additional centers in Shanghai, Hangzhou, and Beijing, China; Waltham, Massachusetts; and Princeton, New Jersey.
Agrivida, Inc.
Series D in 2015
Agrivida, Inc., an animal health and nutrition company, develops feed additives for poultry, swine, dairy and beef cattle, and aquaculture markets. The company offers nutrition solutions for monogastric and ruminant animals, and aquaculture. It offer GRAINZYME, a phytase feed additive for poultry sector. It also provides INzyme Enzymes that deliver regulated enzymes for detergents, oil and gas production, and food applications; and INzyme sugar feedstock advanced bio-based chemical and fuel production. Agrivida, Inc. was founded in 2003 and is based in Four Seasons, Missouri.
Agios Pharmaceuticals
Series A in 2008
Agios Pharmaceuticals is a biopharmaceutical company, discovers and develops therapeutics in the field of cancer metabolism. It also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases. Agios Pharmaceuticals was formerly known as CANCER METABOLISM THERAPEUTICS And changed its name to Agios Pharmaceuticals In April 2008. The company is based in Cambridge, Massachusetts.
AmberWave
Venture Round in 2001
AmberWave, Inc., formerly AmberWave Systems Corporation, engages in the research, development, and licensing of technologies for semiconductor manufacturing. It provides Strained Silicon, a technology that is used in microchips to improve performance and decrease power consumption; and Aspect Ratio Trapping, a technology, which is used to make chips for silicon-based photonics and photovoltaic cells. The company was founded in 1998 and is headquartered in Salem, New Hampshire. AmberWave Systems Corporation is a former subsidiary of U.S. Robotics Corp.
Qwell Pharmaceuticals
Series A in 2009
Qwell's goal is to develop a new family of small-molecule drugs, derived from a plant source, that have a potent ability to fight tumors and excess inflammation of skin cells.
Interline Therapeutics
Series A in 2021
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
It uses genomics, proteomics, structural biology, and computational chemistry to map and modulate protein communities. Interline leverages recent advancements in these technologies, as well as collaborations with leading academic groups, to develop a precision medicine platform focused on three essential areas, genomics, communities, and modulators.
The South San Francisco, California-located company was founded by Zach Sweeney in 2020.
Jaguar Gene Therapy
Series B in 2021
Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases.
Nohla Therapeutics
Series B in 2018
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
Theraclone Sciences, Inc.
Series B in 2007
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.
Genuity Science
Series A in 2013
Genuity Science is a contract genomics and data-sourcing, –analytics and –insights organization headquartered in Boston, Massachusetts, USA with offices in Dublin, Ireland and Reykjavik, Iceland. Genuity partners with global biopharma companies to offer deep end-to-end discovery services aimed at catalyzing precision health and improving the quality of life for patients around the world. Services include population-scale, disease-specific data sourcing, high-quality sequencing, robust statistical analysis and software tools for analyzing large datasets and artificial intelligence (AI). The company operates advanced CAP/CLIA genomics laboratories in Woburn, Massachusetts, USA and in Dublin, Ireland and is deeply committed to data stewardship and data governance across its global offices. For more information, see www.genuitysci.com.
ProjectGuides.com
Series B in 2000
ProjectGuides.com is the premier online marketplace for buyers and sellers of professional services within the architectural, engineering and environmental industries. ProjectGuides.com has pioneered qualifications-based search technology that joins these professionals with public and private buyers.
Backed by a team dedicated to customer satisfaction and success, their system currently tracks professional service opportunities in over 100 industry categories by continuously scanning over 5,000 electronic and print sources. ProjectGuides.com delivers 3,000 leads per week and billions of dollars worth of business opportunities annually to its subscribers, along with industry news and online business tools.
ProjectGuides.com is reinventing how the professional service industry, in the built and natural environment, conducts business. With headquarters in Bellevue, Washington, ProjectGuides.com is a rapidly growing, closely held private company with strategic funding from Alta Partners and ARCH Venture Partners.
Sage Therapeutics, Inc.
Series C in 2014
SAGE Therapeutics is dedicated to the health and well being of patients with central nervous system (CNS) disorders. Their mission is to discover, develop and deliver novel medicines for many of today's most debilitating and disabling CNS disorders by leveraging compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers.
ePolicy
Series A in 2000
ePolicy.com Insurance Services, Inc. (ePolicy) is a business-to-business Internet company that is creating a new way for professionals and small businesses to purchase insurance. Backed by some of the world’s leading insurance companies, such as Fireman’s Fund, ePolicy uses the Internet and proprietary technology to streamline the application and policy-writing process. By creating strategic relationships with major insurance companies and by using the efficiencies of the Internet to reduce costs, ePolicy offers a broad range of insurance products to their customers instantly, with high levels of customer service and significantly reduced rates.
ePolicy is distinctly different from other companies currently offering policies on the Internet. Generally, these companies only replicate the offline process by handing customers over to an agent or broker. At ePolicy, they manage the entire customer experience, from getting a quote to printing the policy. Their staff of dedicated customer service representatives are available by phone and on-line to assist with the application and answer questions.
Vizgen, Inc.
Series B in 2021
Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The high throughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms.
Sorbent Therapeutics
Series B in 2011
Sorbent Therapeutics, Inc. develops treatment for end stage renal disease patients undergoing dialysis. The company develops fluid retaining polymers for therapeutic uses, such as treatment of kidney diseases. Sorbent Therapeutics, Inc. was founded in 2005 and is based in Vernon Hills, Illinois.
Shocking Technologies
Series B in 2009
Shocking Technologies, Inc. started operations as a privately held, venture-backed company developing Voltage Switchable Dielectricâ„¢ (VSDâ„¢) materials. A VSDâ„¢ material is a polymer nano-composite that behaves like an insulator (dielectric) during normal circuit operation and becomes conductive when the voltage across the VSDâ„¢ material increases beyond a predefined threshold voltage. The voltage switches back to an insulator again after the voltage drops below the threshold. This unique property, coupled with the ability to tailor the response of the material, opens up several new areas in electronics. The first application being introduced enables embedded electrostatic discharge (ESD) protection in printed circuit boards (PCBs) and semiconductor packages. Subsequent applications will usher in new manufacturing processes as well as novel product designs.
HiberCell
Series A in 2019
They are proud to be supported by some of the world’s most visionary investors in biotechnology. Their investors share our commitment and vision to change the way they think about and treat metastatic, relapsed cancer.
PhaseRx
Series A in 2008
PhaseRx is a startup company based in Seattle focused on the delivery of siRNA and other macromolecular therapeutics. The Company has attracted top-tier venture investors and was founded by its President, Robert Overell, Patrick Stayton and Allan Hoffman of the University of Washington, Oliver Press of Fred Hutchinson Cancer Research Center, and Paul Johnson, the Company's Chief Scientific Officer. PhaseRx was conceived on the basis of using novel polymer technology to deliver siRNA. The Company believes the technology also has significant applications for the delivery of other macromolecular therapeutics.
Quanterix
Series A in 2008
Quanterix Corporation is developing a novel platform for single molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. Their unique approach permits rapid quantification and analysis of individual proteins and small molecules within complex biological samples, enabling us to address a variety of unmet medical needs. Founded in 2007, Quanterix is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures.
Biopalette
Seed Round in 2018
Biopalette is a operator of a platform intended to offer gene-editing techniques. Bio Palette plans to develop our business in three fields, classified based on the type of cells targeted for genome editing.
KOTURA
Series C in 2008
KOTURA, Inc. provides silicon photonics, designs, manufactures and markets CMOS optical components that enable optics to migrate throughout the communications industry. They also provide custom chip design, fabrication, and packaging services.
Lyell Immunopharma
Series A in 2018
Lyell Immunopharma is focused on advancing the science of T-cell differentiation, functionality, and specificity so that they can develop curative treatments for human diseases.
Lyell Immunopharma is headquartered in South San Francisco, California.
LunaPBC, Inc.
Venture Round in 2019
LunaPBC, Inc. develops a platform for health and DNA research. The company offers LunaDNA, a genomic and medical research knowledge database. Its platform allows individuals to share their health and DNA data for health research and discoveries. It caters to pharmaceutical, insurance, and healthcare information technology (IT) companies. LunaPBC, Inc. was formerly known as Luna DNA Inc. Luna DNA Inc. was incorporated in 2017 and is based in San Diego, California.
Alfalight
Series A in 2000
Alfalight designs and manufactures high-power diode lasers for the industrial, defense, and telecommunications markets. Alfalight's innovative technology is based on advanced aluminum-free active region (ALFA) laser structures, enabling the manufacture of laser diodes with exceptionally high reliability and industry-leading efficiency.
AmberWave
Series E in 2006
AmberWave, Inc., formerly AmberWave Systems Corporation, engages in the research, development, and licensing of technologies for semiconductor manufacturing. It provides Strained Silicon, a technology that is used in microchips to improve performance and decrease power consumption; and Aspect Ratio Trapping, a technology, which is used to make chips for silicon-based photonics and photovoltaic cells. The company was founded in 1998 and is headquartered in Salem, New Hampshire. AmberWave Systems Corporation is a former subsidiary of U.S. Robotics Corp.
AnchorDx
Series B in 2017
Guangzhou Baseline Medical is committed to building a world-class clinical application of high-throughput sequencing and R & D platform to become the leading global provider of precision medical solutions. The company's core team has more than 20 years of senior industry experience, involved in cancer genomics, genetics and bioinformatics and other fields.
Based on its core technical advantages, the Company aims at precision medicine, establishes a cooperative relationship with middle and downstream enterprises in the industry, and forms a complete industrial chain from academic research to clinical product transformation. It has also established close cooperation with many large-scale third-party inspection agencies including Illumina, Well-known domestic and foreign hospitals and research institutes to establish cooperative relations, the development of a series of independent intellectual property rights and international competitiveness of clinical testing products for patients, doctors and medical institutions to provide accurate, convenient and comprehensive services.
Encodia, Inc.
Series C in 2020
Encodia, Inc. engages in proteomics research and creates scalable and parallelized approaches to protein analysis. The company was founded in 2015 and is based in San Diego, California.
Vascular Architects
Series D in 2003
Vascular Architects, Inc. designs, develops, manufactures and markets devices used in the treatment of vascular stenoses, occlusions and non-vascular obstructions. A key area of emphasis is the treatment of peripheral vascular disease, which manifests itself as a reduction or loss of blood flow due to the narrowing or closing of arteries.
Vascular Architects was founded in October 1997 by Thomas J. Fogarty, M.D. Dr Fogarty is an internationally renowned surgeon, professor, inventor and entrepreneur who has founded or cofounded more than 25 start-up companies that develop innovative medical devices. He has authored or coauthored over 150 professional articles, is a member of 29 professional societies, and is an inventor on more than 65 U.S. patents.
Their founder and management team form a highly experienced group of technical, clinical and business personnel. Key opinion leaders in the interventional and vascular surgery communities have been recruited to serve on the Vascular Architects' Scientific Advisory Board.
Nohla Therapeutics
Series A in 2016
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
Be Biopharma
Series B in 2022
Be Biopharma, Inc. develops therapeutics for diseases from engineered B-cells in the immune system. It can overcome the drawbacks of current cell and gene therapies, including the inability to provide multiple doses, unpredictable chemical reactions in some individuals, and the need for chemotherapy regimens prior to cell therapies that can be dangerous to patients. The company applies its technology to diseases, including cancer, autoimmune disorders, and infectious diseases. The company was incorporated in 2020 and is based in Cambridge, Massachusetts.
Proof Diagnostics
Series A in 2022
Proof Diagnostics develops CRISPR‑based COVID‑19 molecular tests to help communities take control of their health.
Singleron Biotechnology Co.,Ltd.
Series B in 2021
Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.
Accumedia
Series C in 2002
Accumedia is a software & services company delivering an industry-specific,
Carrick Therapeutics
Series A in 2016
Carrick Therapeutics is a developer of cancer therapeutics intended to transform the way cancer is treated. The company's therapeutics target molecular pathways that drive the most aggressive and resistant forms of cancer using innovative mechanisms, enabling cancer patients to get their predictive biomarkers detected and get their treatments started from early stage.
Nimble Technology
Series B in 2000
Nimble Technology is an information technology company that is focused on the development of enterprise information integration solutions. It offers a data integration platform that is able to utilize XQuery to build web services and applications such as enterprise information portals and business intelligence systems.
Nimble Technology was acquired by Actuate in July 2003.
Nimble Technology was founded in 1999.
Chiasma
Series D in 2012
Chiasma (Israel) ltd., is a biopharmaceutical company which develops oral drugs based on transient permeability enhancer system. The company offers oral octreotide acetate for the treatment of acromegaly. Its pipeline products include novel drugs which addresses unmet needs for well-defined markets. The company focuses primarily on orphan indications. The company was founded in 2001 and is based in Ness Ziona, Israel. Chiasma (Israel) ltd. operates as a subsidiary of Chiasma, Inc.
bluebird bio, Inc.
Series D in 2012
bluebird bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.
Juno Therapeutics
Series B in 2014
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.
Integrated Diagnostics Inc.
Series A in 2005
The mission of Integrated Diagnostics is to leverage powerful emerging technologies in the development of diagnostic products that enable physicians and patients to manage complex and important diseases such as cancer, diabetes and Alzheimer's through blood tests that can monitor tens to hundreds of disease markers simultaneously. The company plans to develop a pipeline of game-changing diagnostic products that enable the diagnosis and prognosis of a variety of diseases. The company is based on the concept of a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules.
Innovalight
Series C in 2007
Founded by Conrad Burke, Innovalight is focused on bringing high efficiency, low-cost solar modules to the marketplace. Enabling this manufacturing paradigm shift is the company's silicon ink, which has been in development since 2005. Historically, silicon has been processed either as a solid or as a gas. Using liquid based processing Innovalight will dramatically improve the cost and efficiency of today's solar modules.
Univa Corporation
Series A in 2005
Univa is the innovator of workload management solutions that optimize throughput and performance of applications, containers and services. Univa manages workloads automatically by maximizing shared resources and enabling enterprises to scale compute resources across on-premise, hybrid and cloud infrastructures. Univa's solutions help hundreds of companies to manage thousands of applications and run billions of tasks every day to obtain actionable insights and achieve faster time-to-results. Univa is headquartered in Chicago, USA, with offices in Canada and Germany.
Elixir Pharmaceuticals
Series B in 2003
Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.
Arivale
Series B in 2015
Arivale Inc. provides wellness services to individuals. It offers individuals with a scientific path to optimize wellness and avoid diseases. The company’s services engages in analyzing various areas of an individual body, such as genome, blood and saliva, gut microbiome, and lifestyle, as well as provides them with actionable recommendations on optimizing their wellness. In addition, it guides individuals on various types of food and exercise that works with their body. Arivale Inc. was incorporated in 2013 and is headquartered in Seattle, Washington.
Semma Therapeutics
Series B in 2017
Semma Therapeutics, Inc. engages in developing a cell therapy for Type 1 diabetes. It focuses on developing a cell therapy for patients who depend on insulin injections. Semma Therapeutics, Inc. has a strategic collaboration with Defymed. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts with an additional office in Boston, Massachusetts. As of October 10, 2019, Semma Therapeutics, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated.
OncoResponse
Series A in 2016
OncoResponse Inc. is an immuno-oncology company that discovers cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system. It develops human antibody derived therapeutics for the treatment of cancer. The company is based in Houston, Texas.
Allozyne, Inc.
Series A in 2005
Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Its PEGylated IFN beta is for the treatment of multiple sclerosis. The company was founded in 2005 and is based in Seattle, Washington.
VentiRx Pharmaceuticals, Inc.
Series A in 2007
VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops and commercializes Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory, and inflammatory diseases. It provides Motolimod, a lead investigational drug to mobilize a patient's own immune system by directly activating myeloid dendritic cells, monocytes, and natural killer cells to fight cancer. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is based in Seattle, Washington. As of February 28, 2017, VentiRx Pharmaceuticals, Inc. operates as a subsidiary of Celgene Corporation.
Aira Tech Corp.
Series A in 2016
Aira Tech Corp. provides an online platform that operates as a visual interpreter and navigator for blind and low-vision users. Its platform enables orientation and mobility experts, such as trained agents, family members, or friends to provide virtual personal assistance by integrating smart glasses with the user's smartphone. The company was formerly known as Kast Inc. Aira Tech Corp. was incorporated in 2015 and is based in La Jolla, California.
Magnolia NeuroSciences
Series A in 2018
Magnolia Neurosciences aims to discover and develop proprietary, selective, and drug-like small molecule therapeutics for the prevention of neuronal cell death, thereby providing novel treatment options for patients suffering from neurodegeneration and related conditions. Magnolia Neurosciences Corporation, created to pursue technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium (NDC), is a New York-based Accelerator Life Science Partner portfolio company.
Sage Therapeutics, Inc.
Series B in 2013
SAGE Therapeutics is dedicated to the health and well being of patients with central nervous system (CNS) disorders. Their mission is to discover, develop and deliver novel medicines for many of today's most debilitating and disabling CNS disorders by leveraging compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers.
Nanophase Technologies
Venture Round in 1989
Nanophase Technologies Corporation, a skin and sun care focused company, provides engineered materials, formulation development, and commercial manufacturing with an integrated family of technologies in North America and internationally. It offers surface engineered zinc oxide and titanium dioxide for sunscreens and personal care products; fully formulated cosmetics under the Solésence brand name; and advanced materials products, such as architectural coatings, industrial coatings, abrasion-resistant additives, plastics additives, medical diagnostics, and various surface finishing technologies applications. The company was founded in 1989 and is headquartered in Romeoville, Illinois.
MediaPhy
Series A in 2008
MediaPhy is a semiconductor company. Their expertise is design and development of physical (Phy) layer solutions for various Media devices hence the name: MediaPhy!
The company with a core team, started developing the system architecture of what is now flagship product: The MP2011 SoloTM Series Single-Die RF + Baseband Multimode Mobile TV Demodulator
Agios Pharmaceuticals
Series C in 2011
Agios Pharmaceuticals is a biopharmaceutical company, discovers and develops therapeutics in the field of cancer metabolism. It also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases. Agios Pharmaceuticals was formerly known as CANCER METABOLISM THERAPEUTICS And changed its name to Agios Pharmaceuticals In April 2008. The company is based in Cambridge, Massachusetts.
Bit Bio
Series A in 2020
Elpis Biomed aims to become a leading, global supplier of in vitro cell types for academic research and commercial drug discovery & development purposes. The cells could provide an alternative to the limited supply of primary cells and replace animal studies in other cases. Elpis Biomed’s proprietary technology allows rapid generation of highly mature, differentiated cell types at unmatched purity. The process is scalable with the potential to expand product offering with additional cell-types in the neuro-mesoderm focus area. Initial products will be cortical neurons, oligodendrocytes and skeletal muscle cells to be sold to academic research groups and pharma/biotech customers.
Lycera
Series A in 2009
Lycera Corp., a biopharmaceutical company, develops small molecule immunomodulatory medicines for the treatment of autoimmune diseases and cancer. It offers LYC-55716, a multiple anti-tumor mechanism into a single therapeutic by modulating gene expression to reprogram immune cells for improved function, as well as decrease immunosuppressive mechanisms; and ATPase Modulators, a therapy for autoimmune diseases. Lycera Corp. was founded in 2006 and is based in Ann Arbor, Michigan with additional offices in New York, New York; and Plymouth Meeting, Pennsylvania.
Semprius
Series A in 2007
Semprius, Inc. engages in the design, development, manufacture, and supply of high concentration photovoltaic (HCPV) solar modules. The company offers its HCPV solar modules to generate solar energy. Its HCPV solar modules serve utility, commercial/industrial, and government/military applications in sunny and dry locations worldwide. The company delivers its products through integrators and EPCs. Semprius, Inc. was formerly known as pSi-tech, Inc. The company was founded in 2005 and is based in Durham, North Carolina.
JW (Cayman) Therapeutics Co. Ltd
Series B in 2020
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is relmacabtagene autoleucel, an anti-CD19 CAR-T therapy for relapsed or refractory B-cell lymphoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
BIND Therapeutics
Series B in 2007
They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.
Sonoma Biotherapeutics, Inc.
Series A in 2020
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
NexCura
Series C in 2002
NexCura applications and custom services are made available through an application service provider (ASP) model on Web sites and are used to collect comprehensive clinical data and facilitate communication between patients and their physicians. The aggregate data They collect provides direct value to healthcare organizations, pharmaceutical companies, physicians, and patients.
Faraday Pharmaceuticals, Inc.
Series A in 2014
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center.
The company was founded in 2014 and is located in Seattle, Washington.
Adesto Technologies Corporation
Series C in 2011
Adesto Technologies Corporation, Inc. operates as a silicon valley fabless semiconductor company. The company develops next-generation ultralow-power embedded non-volatile memory technology. Adesto Technologies Corporation, Inc. was founded in 2006 and is based in Sunnyvale, California.
Semprius
Series C in 2011
Semprius, Inc. engages in the design, development, manufacture, and supply of high concentration photovoltaic (HCPV) solar modules. The company offers its HCPV solar modules to generate solar energy. Its HCPV solar modules serve utility, commercial/industrial, and government/military applications in sunny and dry locations worldwide. The company delivers its products through integrators and EPCs. Semprius, Inc. was formerly known as pSi-tech, Inc. The company was founded in 2005 and is based in Durham, North Carolina.
Adesto Technologies Corporation
Venture Round in 2010
Adesto Technologies Corporation, Inc. operates as a silicon valley fabless semiconductor company. The company develops next-generation ultralow-power embedded non-volatile memory technology. Adesto Technologies Corporation, Inc. was founded in 2006 and is based in Sunnyvale, California.
Shocking Technologies
Series B in 2010
Shocking Technologies, Inc. started operations as a privately held, venture-backed company developing Voltage Switchable Dielectricâ„¢ (VSDâ„¢) materials. A VSDâ„¢ material is a polymer nano-composite that behaves like an insulator (dielectric) during normal circuit operation and becomes conductive when the voltage across the VSDâ„¢ material increases beyond a predefined threshold voltage. The voltage switches back to an insulator again after the voltage drops below the threshold. This unique property, coupled with the ability to tailor the response of the material, opens up several new areas in electronics. The first application being introduced enables embedded electrostatic discharge (ESD) protection in printed circuit boards (PCBs) and semiconductor packages. Subsequent applications will usher in new manufacturing processes as well as novel product designs.
Cambrios Technologies Corporation
Series D in 2009
Cambrios Technologies Corp. develops electronic materials for the display industry. The company provides wet-processable transparent conductive films. Its nanostructured materials can be deposited using existing production equipment to achieve enhanced performance of display devices and components. The company was founded in 2002 as Semzyme, Inc. and changed its name to Cambrios Technologies Corp. in August 2004. Cambrios Technologies Corp. is based in Sunnyvale, California.
Accelerator Corporation
Series C in 2007
Founded in 2003, Accelerator Corporation is a Seattle-headquartered private equity firm with an office in New York and San Diego. The firm is focused on early-stage investments in biotechnology companies.
Permeon Biologics
Venture Round in 2011
Permeon Biologics aims to enhance human health by using their novel Intraphilin Technology Platform™ to enable intracellular biologics as a revolutionary new generation of therapeutic drugs.
Just Biotherapeutics, Inc.
Series A in 2015
Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.
Sorbent Therapeutics
Series C in 2012
Sorbent Therapeutics, Inc. develops treatment for end stage renal disease patients undergoing dialysis. The company develops fluid retaining polymers for therapeutic uses, such as treatment of kidney diseases. Sorbent Therapeutics, Inc. was founded in 2005 and is based in Vernon Hills, Illinois.
Midstream Technologies
Series C in 2002
MidStream Technologies(TM) has developed the world's first dedicated streaming appliance. One box can deliver 16,000 simultaneous broadband streams with unprecedented scalability. A multiple box configuration provides built-in load balancing, failover reliability and the power to deliver millions of concurrent streams. MidStream servers can support every popular streaming format simultaneously & allow for software and appliance upgrades in the field, extending hardware longevity and promoting cost savings.
Biopalette
Venture Round in 2017
Biopalette is a operator of a platform intended to offer gene-editing techniques. Bio Palette plans to develop our business in three fields, classified based on the type of cells targeted for genome editing.
Semprius
Venture Round in 2012
Semprius, Inc. engages in the design, development, manufacture, and supply of high concentration photovoltaic (HCPV) solar modules. The company offers its HCPV solar modules to generate solar energy. Its HCPV solar modules serve utility, commercial/industrial, and government/military applications in sunny and dry locations worldwide. The company delivers its products through integrators and EPCs. Semprius, Inc. was formerly known as pSi-tech, Inc. The company was founded in 2005 and is based in Durham, North Carolina.
Surface Logix
Series D in 2007
Surface Logix is a drug development company which uses its expertise in biophysical chemistry to create new small molecule drugs with significantly improved pharmacokinetic (PK) and pharmacodynamic (PD) properties compared with class leaders.
SilverStorm Technologies
Venture Round in 2002
SilverStorm Technologies provides networking and clustered interconnect solutions for high performance business computing markets. It designs and manufactures an InfiniBand based set of solutions for the performance and I/O requirements of data center environments that utilize clustered topologies. The company markets its products through direct sales, and channel and technology partners globally. SilverStorm Technologies, Inc. was founded as InfiniCon Systems, Inc. in 2000 and changed its name to SilverStorm Technologies, Inc. in 2005. The company is headquartered in King of Prussia, Pennsylvania. As of November 01, 2006, SilverStorm Technologies, Inc. operates as a subsidiary of QLogic Corp.
Alnylam Pharmaceuticals
Venture Round in 2003
Alnylam (Nasdaq: ALNY) is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
Fate Therapeutics, Inc.
Series B in 2009
Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics.
The company has brought together the foremost scientists from the nation's research hotbeds (Boston, San Francisco, San Diego, and Seattle) who have demonstrated the potential to create and modulate stem cells to restore health.
The backstory is that while others were working towards therapies based on transplanting stem cell-derived cells into patients, Randall Moon (HHMI and the University of Washington) and Alex Rives (Arch Venture Capitol) envisioned a different approach to develop regenerative therapies. The concept, based on data from hematopoietic progenitor cells, was that one could modulate the properties of stem cells in vivo using small molecules or biologics. They presented this idea to Arch Venture Capitol in Seattle, which launched the company, soon to be joined by other investors.
VBI Vaccines Inc.
Post in 2016
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
VBI is headquartered in Cambridge, MA with research facilities in Ottawa, Canada.
HiberCell
Series B in 2021
They are proud to be supported by some of the world’s most visionary investors in biotechnology. Their investors share our commitment and vision to change the way they think about and treat metastatic, relapsed cancer.
Glympse Bio
Series B in 2020
Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis.
Glympse Bio’s platform technology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering.
Nanosys
Series E in 2012
Nanosys, Inc. develops and delivers quantum dot technology for high definition viewing experience for the display industry. It offers Quantum Dot Concentrate material; quantum dot nanomaterials; and Quantum Dot Enhancement film to industrial supply chain partners. Its products are used in tablets, televisions, smartphones, and other consumer electronics applications. Nanosys, Inc. was incorporated in 2001 and is based in Milpitas, California.
Sana Biotechnology, Inc.
Seed Round in 2019
Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients.
Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases.
The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.
Transcenta Holding Ltd.
Venture Round in 2019
Transcenta Holding Ltd., a biotherapeutics company, engages in the research and development and manufacturing of antibody-based therapeutics. The company also offers clinical researches and trial services. Transcenta Holding Ltd. was founded in 2019 and is based in Suzhou, China. It has additional centers in Shanghai, Hangzhou, and Beijing, China; Waltham, Massachusetts; and Princeton, New Jersey.
Insitro
Series A in 2018
Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.
Amphora Discovery
Series D in 2005
Amphora Discovery Corporation operates as a biotechnology company. It provides integrated services to the pharmaceutical industry. The company's products and services include in vitro assay protocols, in vitro throughput screening and compound profiling services, custom assay development, enzymology services, and lead discovery/lead optimization partnering programs. It offers drug discovery contract research services, HTS, profiling and lead generation, and lead optimization solutions. The company serves pharmaceutical and biopharmaceutical companies, emerging biotechnology companies, and research foundations. Amphora Discovery Corporation was founded in 2001 and is headquartered in Durham, North Carolina. As of July 2008, Amphora Discovery Corporation operates as a subsidiary of Nanosyn Inc.
Idun Handel & Industri AB
Series A in 2002
IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.
Ultivue
Series A in 2015
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
It was founded in 2015 and headquartered in Cambridge, Massachusetts.
Remix Therapeutics
Series A in 2020
Remix Therapeutics Inc. engages in the biotech research and development business. It discovers and develops various novel therapeutic RNA processing modulators to target various undruggable disease drivers. The company also offers biology platform to identify and prioritize targets with therapeutically-tractable intervention points in RNA processing. Its REMseq platform validates targets and chemical matter discovery and optimization. The company was founded in 2018 and is based in Cambridge, Massachusetts.
Appliant.com
Venture Round in 2000
Appliant.com is the technology leader in monitoring Web infrastructure and application performance, availability and usage, with a focus on customer experience. Founded in 1997 in Seattle, Appliant.com helps e-businesses, enterprises and service providers maximize their return on investment in Web applications and infrastructure. Provided as an ASP solution, Appliant.com's Lateral Line Network monitors and reports Internet transactions through robust, unobtrusive monitors deployed across the Internet. Using real data from real users, the service provides a customer-centric view of a company's Web site performance, availability and usage. The company is privately held.
Unity Biotechnology, Inc.
Series B in 2016
Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.
Innovalight
Venture Round in 2009
Founded by Conrad Burke, Innovalight is focused on bringing high efficiency, low-cost solar modules to the marketplace. Enabling this manufacturing paradigm shift is the company's silicon ink, which has been in development since 2005. Historically, silicon has been processed either as a solid or as a gas. Using liquid based processing Innovalight will dramatically improve the cost and efficiency of today's solar modules.
Ensemble Therapeutics Corporation
Series A in 2004
Ensemble Therapeutics Corporation discovers and develops small molecule therapies for patients with cancer and other serious diseases. The company builds a pipeline of therapies that primarily focuses on immuno-oncology programs that include Indoleamine 2, 3-dioxygenase 1 (IDO-1), an intracellular immune checkpoint protein that catalyzes the breakdown of the essential amino acid tryptophan; ubiquitin proteasome system programs, such as Ubiquitin-specific protease 9x, which elevates levels of oncoprotein MCL1 that causes the survival of highly metastatic tumors, including melanoma, glioblastoma, and triple-negative breast and tumors. It also provides inhibitors of apoptosis proteins, such as XIAP and cIAP, which are a family of cancer-promoting proteins that inhibits tumor cell death by binding to the caspase enzymes that cause apoptosis; and Cyclophilins, a family of proteins that responsible for the isomerization of peptide bonds and thus facilitate protein folding. Ensemble Therapeutics Corporation was formerly known as Ensemble Discovery Corporation and changed its name to Ensemble Therapeutics Corporation in June 2010. The company was incorporated in 2002 and is based in Cambridge, Massachusetts.
Insitro
Series A in 2019
Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.
Alfalight
Series C in 2002
Alfalight designs and manufactures high-power diode lasers for the industrial, defense, and telecommunications markets. Alfalight's innovative technology is based on advanced aluminum-free active region (ALFA) laser structures, enabling the manufacture of laser diodes with exceptionally high reliability and industry-leading efficiency.
Ikaria
Series B in 2007
Ikaria develop and deliver innovative therapeutics and interventions to meet the significant needs of critically ill patients. It is our aim to be an indispensable partner to clinicians, providing help and critically caring just when patients need it the most.
Allozyne, Inc.
Series B in 2007
Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Its PEGylated IFN beta is for the treatment of multiple sclerosis. The company was founded in 2005 and is based in Seattle, Washington.
Achaogen
Series B in 2006
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.
Bellerophon Therapeutics, Inc.
Series A in 2013
Bellerophon Therapeutics LLC is a clinical stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitric oxide delivery device, INOpulse®, and are in Phase 2 clinical trials – one for the treatment of PAH and a second for the treatment of PH-COPD. The company's third product candidate, bioabsorbable cardiac matrix (BCM), is an injectable device currently undergoing a feasibility clinical trial, which is a CE mark registration trial in the European Union and is comparable to a Phase 2 trial in U.S. drug development, for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction (heart attack).
Kythera Biopharmaceuticals
Series C in 2008
KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California.
KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.
Mindstrong Inc.
Series B in 2018
Mindstrong Health develops comprehensive care pathways based on passively-collected, continuous and objective measures of cognitive function and mood. Solutions include a patient-facing app, a provider-facing product, and clinical services that leverage its telehealth enabled measurement science and engagement platform. Mindstrong is partnered with leading organizations committed to advancing medical innovation and improving healthcare delivery for patients, including pharmaceutical companies, large payers and providers, large employers, and state and county governments, in addition to top-tier academic institutions for clinical research.
Impinj, Inc.
Series D in 2005
Impinj is a provider of RAIN RFID solutions that deliver Item Intelligence to retail, pharmaceutical, healthcare, food and beverage, and many other industries. We enable the Internet of Things to identify, locate and authenticate billions of items, and our Item Intelligence platform comprises the most comprehensive and widely adopted RAIN RFID product portfolio in the world. For more information about Impinj, visit www.impinj.com.
Remix Therapeutics
Series B in 2022
Remix Therapeutics Inc. engages in the biotech research and development business. It discovers and develops various novel therapeutic RNA processing modulators to target various undruggable disease drivers. The company also offers biology platform to identify and prioritize targets with therapeutically-tractable intervention points in RNA processing. Its REMseq platform validates targets and chemical matter discovery and optimization. The company was founded in 2018 and is based in Cambridge, Massachusetts.
Scholar Rock Holding Corporation
Series A in 2014
Scholar Rock, Inc., a biotechnology company, discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.
Xenoport
Series A in 2000
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.
Kythera Biopharmaceuticals
Series D in 2011
KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California.
KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.
AmberWave
Series B in 2002
AmberWave, Inc., formerly AmberWave Systems Corporation, engages in the research, development, and licensing of technologies for semiconductor manufacturing. It provides Strained Silicon, a technology that is used in microchips to improve performance and decrease power consumption; and Aspect Ratio Trapping, a technology, which is used to make chips for silicon-based photonics and photovoltaic cells. The company was founded in 1998 and is headquartered in Salem, New Hampshire. AmberWave Systems Corporation is a former subsidiary of U.S. Robotics Corp.
ONI (Oxford Nanoimaging)
Series B in 2021
Oxford NanoImaging Limited develops and manufactures microscope. It offers Nanoimager, a single-molecule fluorescence microscope which enables researchers to detect biomolecules, such as protein markers for disease or pathogenic bacteria, and viruses at single copy numbers with single-molecule imaging, 3D, and dual-color super-resolution functionality. It also offers Förster Resonance Energy Transfer microscopy technology that reports distances in real time; direct stochastic optical reconstruction microscopy (dSTORM); and photoactivated localization microscopy (PALM) technology based microscope. Oxford NanoImaging Limited was incorporated in 2016 and is based in London, United Kingdom. The company has additional office in Menlo Park, California.
Karuna Pharmaceuticals
Series B in 2019
Karuna Pharmaceuticals, Inc. engages in development of drugs for the treatment of schizophrenia. The company was incorporated in 2009 and is based in Boston, Massachusetts.
Gossamer Bio, Inc.
Series B in 2018
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
HiberCell
Series A in 2019
They are proud to be supported by some of the world’s most visionary investors in biotechnology. Their investors share our commitment and vision to change the way they think about and treat metastatic, relapsed cancer.
Generate Biomedicines
Series B in 2021
Generate Biomedicines, Inc. develops a platform to invent novel antibodies, peptides, enzymes, receptors, and other therapeutic proteins. It offers Generative Biology, a machine learning based solution that learns from all known proteins in order to encode and apply the fundamental principles of how genetic sequences lead to protein structure and function for creating novel protein sequences with optimized therapeutic potential. Its Generative Biology is applied to all protein modalities and generate novel proteins with desired functions and solutions that interact potently and specifically with therapeutic targets. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in March 2020. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Scholar Rock Holding Corporation
Series B in 2016
Scholar Rock, Inc., a biotechnology company, discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.
Just Biotherapeutics, Inc.
Series A in 2016
Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.
Sonoma Biotherapeutics, Inc.
Series A in 2020
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
Sorbent Therapeutics
Series D in 2014
Sorbent Therapeutics, Inc. develops treatment for end stage renal disease patients undergoing dialysis. The company develops fluid retaining polymers for therapeutic uses, such as treatment of kidney diseases. Sorbent Therapeutics, Inc. was founded in 2005 and is based in Vernon Hills, Illinois.
AmberWave
Series D in 2004
AmberWave, Inc., formerly AmberWave Systems Corporation, engages in the research, development, and licensing of technologies for semiconductor manufacturing. It provides Strained Silicon, a technology that is used in microchips to improve performance and decrease power consumption; and Aspect Ratio Trapping, a technology, which is used to make chips for silicon-based photonics and photovoltaic cells. The company was founded in 1998 and is headquartered in Salem, New Hampshire. AmberWave Systems Corporation is a former subsidiary of U.S. Robotics Corp.
Codiak BioSciences, Inc.
Series A in 2015
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
SilverStorm Technologies
Series A in 2005
SilverStorm Technologies provides networking and clustered interconnect solutions for high performance business computing markets. It designs and manufactures an InfiniBand based set of solutions for the performance and I/O requirements of data center environments that utilize clustered topologies. The company markets its products through direct sales, and channel and technology partners globally. SilverStorm Technologies, Inc. was founded as InfiniCon Systems, Inc. in 2000 and changed its name to SilverStorm Technologies, Inc. in 2005. The company is headquartered in King of Prussia, Pennsylvania. As of November 01, 2006, SilverStorm Technologies, Inc. operates as a subsidiary of QLogic Corp.
Omeros
Series E in 2007
Omeros is a Seattle-based commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system.
OncoResponse
Series C in 2021
OncoResponse Inc. is an immuno-oncology company that discovers cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system. It develops human antibody derived therapeutics for the treatment of cancer. The company is based in Houston, Texas.
AgBiome, LLC
Venture Round in 2014
AgBiome, LLC, a biotechnology company, engages in delivering research and discovery to the agriculture industry. The company develops biological product that controls the predominant soil-borne diseases of greenhouse and major row crops. It identifies plant-associated microbes that enhance plant health, pest resistance, and yield applying based on genomics and screening technologies. AgBiome, LLC has strategic partnerships with Genective and ElevateBio. The company was incorporated in 2012 and is based in Durham, North Carolina.
Juno Therapeutics
Series A in 2013
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.
908 Devices Inc.
Series C in 2015
908 Devices is bringing the powerful capabilities of Mass Spectrometry out of the confines of centralized facilities and mobile laboratories. The company makes battery-operated, handheld, chemical detection tools, rugged enough to exceed military standards, and trusted enough for immediate action in the field. For biologists and chemists in need of answers, 908 Devices makes personal analyzers, small and simple enough for every workspace.
Nanosys
Seed Round in 2001
Nanosys, Inc. develops and delivers quantum dot technology for high definition viewing experience for the display industry. It offers Quantum Dot Concentrate material; quantum dot nanomaterials; and Quantum Dot Enhancement film to industrial supply chain partners. Its products are used in tablets, televisions, smartphones, and other consumer electronics applications. Nanosys, Inc. was incorporated in 2001 and is based in Milpitas, California.
Sienna Biopharmaceuticals, Inc.
Series A in 2016
Sienna Biopharmaceuticals (“sienna”) is a company focused on the discovery, clinical development and commercialization of products in aesthetics and dermatology based on scientific breakthroughs that dramatically improve patient outcomes and physicians’ practice of medicine.
Pheast Therapeutics
Series A in 2022
Theraclone Sciences, Inc.
Venture Round in 2011
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.
Ultivue
Series D in 2021
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
It was founded in 2015 and headquartered in Cambridge, Massachusetts.
Eichrom Europe SAS
Venture Round in 1994
Eichrom Europe SAS provides analytical testing services. The company specializes in the measurement of radioactivity, chemical compounds, and asbestos in radioactive or potentially-radioactive samples. It measures radioactivity in a range of business sectors, such as decommissioning and dismantling, environmental monitoring of nuclear sites, testing drinking water, radioprotection, and foodstuff sectors. The company was founded in 2003 and is based in Bruz, France. As of April 4, 2018, Eichrom Europe SAS operates as a subsidiary of Eurofins Scientific SE.
GenVec Inc.
Venture Round in 1992
GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).
Kura Oncology, Inc.
Venture Round in 2015
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company’s lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Ikaria
Series A in 2005
Ikaria develop and deliver innovative therapeutics and interventions to meet the significant needs of critically ill patients. It is our aim to be an indispensable partner to clinicians, providing help and critically caring just when patients need it the most.
Hua Medicine
Series A in 2011
Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.
VentiRx Pharmaceuticals, Inc.
Series A in 2010
VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops and commercializes Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory, and inflammatory diseases. It provides Motolimod, a lead investigational drug to mobilize a patient's own immune system by directly activating myeloid dendritic cells, monocytes, and natural killer cells to fight cancer. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is based in Seattle, Washington. As of February 28, 2017, VentiRx Pharmaceuticals, Inc. operates as a subsidiary of Celgene Corporation.
Shocking Technologies
Series C in 2011
Shocking Technologies, Inc. started operations as a privately held, venture-backed company developing Voltage Switchable Dielectricâ„¢ (VSDâ„¢) materials. A VSDâ„¢ material is a polymer nano-composite that behaves like an insulator (dielectric) during normal circuit operation and becomes conductive when the voltage across the VSDâ„¢ material increases beyond a predefined threshold voltage. The voltage switches back to an insulator again after the voltage drops below the threshold. This unique property, coupled with the ability to tailor the response of the material, opens up several new areas in electronics. The first application being introduced enables embedded electrostatic discharge (ESD) protection in printed circuit boards (PCBs) and semiconductor packages. Subsequent applications will usher in new manufacturing processes as well as novel product designs.
Verve Therapeutics
Series A in 2019
Verve Therapeutics, Inc. develops therapies for editing the adult human genomes. It utilizes human genetic analysis and gene-editing technology for developing therapies to reduce the risk of coronary artery diseases. The company serves the biotechnology and health care sectors. It has a strategic alliance with Beam Therapeutics for developing delivery technologies against cardiovascular targets; and Verily, for the development of gene editing delivery vehicles. Verve Therapeutics, Inc. was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in September 2019. The company was founded in 2018 and is based in Cambridge, Massachusetts with a research facility in Philadelphia, Pennsylvania.
Excision BioTherapeutics Inc.
Series A in 2021
Excision BioTherapeutics is a private company focused on developing advanced gene-editing therapeutics to address the medical need for the treatment of life-threatening diseases caused by viral infections. They develop gene-editing medicines that eradicate or disrupt viral genes in human patients. Their mission is to advance gene-editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.
Aledade
Series B in 2015
Aledade, Inc. provides services to primary care physicians to form and operate accountable care organizations (ACO) in the United States. It offers primary care providers access to data analytics, user-friendly guided workflows, regulatory expertise, payer relationships, and local support from attentive experts. The company also provides 360° practice support, workflow optimization, ACO governance, policy expertise, and contracting support services. It serves small practices, large practices, FQHCS/community health centers, and multispecialty groups. Aledade, Inc. was incorporated in 2014 and is based in Bethesda, Maryland.
Cytrellis Biosystems
Series A in 2015
Cytrellis Biosystems is a clinical stage medical technology company that designs and develops medical device for dermatology, scar reduction, and aesthetic medicine. Its devices are designed to remove sagging skin associated with aging without surgery or scarring, providing aesthetic practitioners an unprecedented ability to improve age related changes in skin.
Cytrellis Biosystems was founded in 2011 and is based in Boston, Massachusetts.
Vizgen, Inc.
Series C in 2022
Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The high throughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms.
Reef Point Systems
Series D in 2004
As of December 2007, Reef Point Systems, Inc. was acquired by NextPoint Networks, Inc. Reef Point Systems, Inc. provides security solutions for converged wireless and wireline networks in the United States. Its iQ product portfolio enables fixed/mobile convergence security, secure mobile access, network infrastructure protection, and managed security services. It enables operators to secure voice over the Internet protocol, Internet protocol television, and voice, video, and data services from a converged Internet protocol infrastructure. The company’s iQ family lets wireless service providers protect the wireless network infrastructure and deliver multimedia services for mobile users over unlicensed mobile access and Internet protocol multimedia subsystem infrastructure. Its products also enable service providers to offer various security services, including virtual private networks, firewalls, denial of service attack prevention, content filtering, and remote access.
The company, formerly known as Quarry Technologies, Inc., was founded in 1998 and is headquartered in Burlington, Massachusetts.
Amphora Discovery
Series B in 2002
Amphora Discovery Corporation operates as a biotechnology company. It provides integrated services to the pharmaceutical industry. The company's products and services include in vitro assay protocols, in vitro throughput screening and compound profiling services, custom assay development, enzymology services, and lead discovery/lead optimization partnering programs. It offers drug discovery contract research services, HTS, profiling and lead generation, and lead optimization solutions. The company serves pharmaceutical and biopharmaceutical companies, emerging biotechnology companies, and research foundations. Amphora Discovery Corporation was founded in 2001 and is headquartered in Durham, North Carolina. As of July 2008, Amphora Discovery Corporation operates as a subsidiary of Nanosyn Inc.
Hangzhou Just Biotherapeutics (Just China)
Series B in 2018
Hangzhou Just Biotherapeutics, Ltd., also known as Just China, develops antibody and recombinant protein bio-therapeutics. The company was founded in 2016 and is based in Hangzhou, China. Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of Just Biotherapeutics, Inc. As of January 2, 2019, Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of MabSpace Biosciences Co., Ltd..
Faraday Pharmaceuticals, Inc.
Series B in 2019
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center.
The company was founded in 2014 and is located in Seattle, Washington.
Omniome
Series B in 2018
Omniome engages in developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy. Backed by leading life sciences venture investors and a proven management team, Omniome’s vision is to be the most trusted DNA sequencing platform and leader in clinical sequencing.
Founded in 2013, the company is headquartered in San Diego, California, United States.
Receptos
Venture Round in 2012
Receptos is a privately-held drug discovery and development company which utilizes pioneering G protein-coupled receptor (GPCR) technology to facilitate information-driven drug design for developing best- and first-in-class drugs.
Locana
Series A in 2019
Locanabio, Inc., is an RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.
EQRx
Series B in 2021
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
Theraclone Sciences, Inc.
Series B in 2013
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.
AgBiome, LLC
Series A in 2013
AgBiome, LLC, a biotechnology company, engages in delivering research and discovery to the agriculture industry. The company develops biological product that controls the predominant soil-borne diseases of greenhouse and major row crops. It identifies plant-associated microbes that enhance plant health, pest resistance, and yield applying based on genomics and screening technologies. AgBiome, LLC has strategic partnerships with Genective and ElevateBio. The company was incorporated in 2012 and is based in Durham, North Carolina.
Fate Therapeutics, Inc.
Series B in 2011
Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics.
The company has brought together the foremost scientists from the nation's research hotbeds (Boston, San Francisco, San Diego, and Seattle) who have demonstrated the potential to create and modulate stem cells to restore health.
The backstory is that while others were working towards therapies based on transplanting stem cell-derived cells into patients, Randall Moon (HHMI and the University of Washington) and Alex Rives (Arch Venture Capitol) envisioned a different approach to develop regenerative therapies. The concept, based on data from hematopoietic progenitor cells, was that one could modulate the properties of stem cells in vivo using small molecules or biologics. They presented this idea to Arch Venture Capitol in Seattle, which launched the company, soon to be joined by other investors.
Sorbent Therapeutics
Series B in 2010
Sorbent Therapeutics, Inc. develops treatment for end stage renal disease patients undergoing dialysis. The company develops fluid retaining polymers for therapeutic uses, such as treatment of kidney diseases. Sorbent Therapeutics, Inc. was founded in 2005 and is based in Vernon Hills, Illinois.
Receptos
Series B in 2013
Receptos is a privately-held drug discovery and development company which utilizes pioneering G protein-coupled receptor (GPCR) technology to facilitate information-driven drug design for developing best- and first-in-class drugs.
Pulmatrix
Post in 2015
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.
Siluria Technologies Inc.
Series C in 2012
Siluria Technologies is a materials innovation company solving global challenges for partners in the natural gas, chemicals and fuel industries. Integrating nanotechnology, biotechnology and chemical engineering, Siluria has developed a solution to the grand challenge of efficient manufacturing: the ability to produce chemicals and fuels from a cheaper, more abundant resource than oil. The company's economically superior, energy-efficient platform converts natural gas into the same materials manufactured today using current industry infrastructure. Siluria's world-class R&D and engineering teams are rapidly commercializing the company's technology to pilot-scale production in close dialogue with the world's largest chemical and fuel companies.Siluria's backers include Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.
Nutcracker Therapeutics
Series C in 2022
Nutcracker Therapeutics, Inc. develops mRNA therapeutics to produce mRNA and delivery vehicle formulations on single-use biochips. The company provides a push-button mRNA synthesis and formulation platform. The company was incorporated in 2017 and is based in Emeryville, California.
ImmuneID
Series A in 2021
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.
hC Bioscience
Series A in 2022
Hua Medicine
Series C in 2016
Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.
Sesh Therapy Incorporated
Seed Round in 2020
Sesh is a mental health company providing access to group support via a mobile app. It offers a variety of sessions led by top mental health professionals for a fraction of the market price of a standard therapy appointment.
The company was founded in 2020 and is headquartered in San Francisco, California.
Hua Medicine
Series B in 2015
Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.
Kythera Biopharmaceuticals
Series B in 2006
KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California.
KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.
Beam Therapeutics Inc.
Series B in 2019
Over half of the genetic errors associated with disease result from a single-letter change in the billions of bases that form the genome. In other cases, certain natural genetic variations in DNA are known to protect against disease. By changing a single letter – to eliminate errors or write in protective changes – in enough cells, base editing may help us prevent, modify, and even cure a wide range of diseases affecting patients’ lives.
ROME Therapeutics, Inc.
Series B in 2021
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.
Cardero Therapeutics
Series A in 2019
Cardero Therapeutics is a start-up pharmaceutical company that is developing a novel class of therapeutics that induces the formation of new mitochondria (mitochondrial biogenesis) and enhances mitochondrial function in response to metabolic demand. Chronic depletion of mitochondria, the principal source of cellular ATP, has been directly linked to the progression of heart failure, sarcopenia, and neurodegeneration. Cardero Therapeutics is collaborating with numerous academic medical centers to advance novel drug candidates structurally based on a newly discovered human hormone that appears to fundamentally regulate mitochondrial density and function in all tissues. Cardero Therapeutics believes that enhancing myocyte bioenergetics will comprise an innovative therapeutic approach complementary to currently available cardiovascular drugs. The company’s clinical development focus is the lethal cardiomyopathy associated with orphan diseases characterized by loss of mitochondria in muscle and heart, resulting in heart failure that is poorly responsive to current medical interventions. Initial clinical trials are directed toward Duchenne muscular dystrophy and Friedreich’s ataxia.
Voxel8
Series B in 2019
Voxel8 Inc. designs and manufactures electronic devices. It offers desktop 3D printers that are used to print thermoplastics or UV resins. The company also provides Project Wire, a cloud software tool that is used for designing 3D printable electronic devices that can be rapidly fabricated using the Voxel8 3D printer. Voxel8 Inc. was incorporated in 2013 and is based in Somerville, Massachusetts.
Verve Therapeutics
Series A in 2020
Verve Therapeutics, Inc. develops therapies for editing the adult human genomes. It utilizes human genetic analysis and gene-editing technology for developing therapies to reduce the risk of coronary artery diseases. The company serves the biotechnology and health care sectors. It has a strategic alliance with Beam Therapeutics for developing delivery technologies against cardiovascular targets; and Verily, for the development of gene editing delivery vehicles. Verve Therapeutics, Inc. was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in September 2019. The company was founded in 2018 and is based in Cambridge, Massachusetts with a research facility in Philadelphia, Pennsylvania.
New Era of Networks
Series A in 1995
New Era Technologies is a U.S.-based R&D technology company. The company develops markets and supports application integration software and provides application integration services.
The company’s main product is NeoNet, software that facilitates the rapid and efficient deployment and ongoing maintenance of application integration across the enterprise.
The company was acquired by Sybase in 2001.
The company was founded in 1995 and is based in Colorado.
Cytrellis Biosystems
Series B in 2018
Cytrellis Biosystems is a clinical stage medical technology company that designs and develops medical device for dermatology, scar reduction, and aesthetic medicine. Its devices are designed to remove sagging skin associated with aging without surgery or scarring, providing aesthetic practitioners an unprecedented ability to improve age related changes in skin.
Cytrellis Biosystems was founded in 2011 and is based in Boston, Massachusetts.
Sienna Biopharmaceuticals, Inc.
Series A in 2016
Sienna Biopharmaceuticals (“sienna”) is a company focused on the discovery, clinical development and commercialization of products in aesthetics and dermatology based on scientific breakthroughs that dramatically improve patient outcomes and physicians’ practice of medicine.
Voxel8
Series A in 2015
Voxel8 Inc. designs and manufactures electronic devices. It offers desktop 3D printers that are used to print thermoplastics or UV resins. The company also provides Project Wire, a cloud software tool that is used for designing 3D printable electronic devices that can be rapidly fabricated using the Voxel8 3D printer. Voxel8 Inc. was incorporated in 2013 and is based in Somerville, Massachusetts.
Hangzhou Just Biotherapeutics (Just China)
Series B in 2017
Hangzhou Just Biotherapeutics, Ltd., also known as Just China, develops antibody and recombinant protein bio-therapeutics. The company was founded in 2016 and is based in Hangzhou, China. Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of Just Biotherapeutics, Inc. As of January 2, 2019, Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of MabSpace Biosciences Co., Ltd..
Sana Biotechnology, Inc.
Series A in 2020
Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients.
Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases.
The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.
KOTURA
Series B in 2005
KOTURA, Inc. provides silicon photonics, designs, manufactures and markets CMOS optical components that enable optics to migrate throughout the communications industry. They also provide custom chip design, fabrication, and packaging services.
Teach.com
Venture Round in 2000
Teach.com is an all-inclusive educational web resource dedicated to discovering, discussing, and encouraging teaching around the world. It provides current teachers an easy-to-navigate map outlining the steps to become a teacher, including information on teacher salaries, teacher preparation, and certification requirements for all 50 states as well as information on teaching abroad.
It offers current teachers in STEM, and other fields, with the opportunity to receive information about the USC Rossier Online, the top-ranked teacher preparation program delivered online from the University of Southern California.
Teach.com is based in Elk Grove Village, I.L.
Dewpoint Therapeutics
Series B in 2020
Dewpoint Therapeutics, Inc., a biotech company, engages in research of biomolecular condensates and cellular function to develop treatments for diseases like cancer, neurodegenerative disorders, immunology, cardiovascular, women’s health, and virology. The company was incorporated in 2018 and is based in Boston, Massachusetts.
eCustomers.com
Series B in 2000
eCustomers, Inc. is revolutionizing the way consumers interact with businesses online. To empower consumers, eCustomers, Inc. was created to be a pioneer and leading Internet-based infomediary that delivers valuable personalized content to eBusiness systems.
LifeMine Therapeutics
Series C in 2022
LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional office in New York, New York.
Xtera
Venture Round in 2007
Xtera Communications, Inc. is in the process of liquidation. Previously, it provided Raman amplification enabled optical transport systems for terrestrial and submarine networks worldwide. The company was founded in 1998 and is headquartered in Allen, Texas. On February 21, 2017, the voluntary petition of Xtera Communications, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on November 15, 2016.
Impinj, Inc.
Venture Round in 2012
Impinj is a provider of RAIN RFID solutions that deliver Item Intelligence to retail, pharmaceutical, healthcare, food and beverage, and many other industries. We enable the Internet of Things to identify, locate and authenticate billions of items, and our Item Intelligence platform comprises the most comprehensive and widely adopted RAIN RFID product portfolio in the world. For more information about Impinj, visit www.impinj.com.
Midstream Technologies
Series B in 2001
MidStream Technologies(TM) has developed the world's first dedicated streaming appliance. One box can deliver 16,000 simultaneous broadband streams with unprecedented scalability. A multiple box configuration provides built-in load balancing, failover reliability and the power to deliver millions of concurrent streams. MidStream servers can support every popular streaming format simultaneously & allow for software and appliance upgrades in the field, extending hardware longevity and promoting cost savings.
Twist Bioscience Corporation
Series B in 2014
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Cambrios Technologies Corporation
Series A in 2004
Cambrios Technologies Corp. develops electronic materials for the display industry. The company provides wet-processable transparent conductive films. Its nanostructured materials can be deposited using existing production equipment to achieve enhanced performance of display devices and components. The company was founded in 2002 as Semzyme, Inc. and changed its name to Cambrios Technologies Corp. in August 2004. Cambrios Technologies Corp. is based in Sunnyvale, California.
Elephas
Series B in 2022
Fate Therapeutics, Inc.
Series A in 2007
Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics.
The company has brought together the foremost scientists from the nation's research hotbeds (Boston, San Francisco, San Diego, and Seattle) who have demonstrated the potential to create and modulate stem cells to restore health.
The backstory is that while others were working towards therapies based on transplanting stem cell-derived cells into patients, Randall Moon (HHMI and the University of Washington) and Alex Rives (Arch Venture Capitol) envisioned a different approach to develop regenerative therapies. The concept, based on data from hematopoietic progenitor cells, was that one could modulate the properties of stem cells in vivo using small molecules or biologics. They presented this idea to Arch Venture Capitol in Seattle, which launched the company, soon to be joined by other investors.
Prime Medicine
Series A in 2019
Pretzel Therapeutics
Series A in 2022
Codiak BioSciences, Inc.
Series B in 2016
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
908 Devices Inc.
Series B in 2013
908 Devices is bringing the powerful capabilities of Mass Spectrometry out of the confines of centralized facilities and mobile laboratories. The company makes battery-operated, handheld, chemical detection tools, rugged enough to exceed military standards, and trusted enough for immediate action in the field. For biologists and chemists in need of answers, 908 Devices makes personal analyzers, small and simple enough for every workspace.
Amphora Discovery
Series A in 2001
Amphora Discovery Corporation operates as a biotechnology company. It provides integrated services to the pharmaceutical industry. The company's products and services include in vitro assay protocols, in vitro throughput screening and compound profiling services, custom assay development, enzymology services, and lead discovery/lead optimization partnering programs. It offers drug discovery contract research services, HTS, profiling and lead generation, and lead optimization solutions. The company serves pharmaceutical and biopharmaceutical companies, emerging biotechnology companies, and research foundations. Amphora Discovery Corporation was founded in 2001 and is headquartered in Durham, North Carolina. As of July 2008, Amphora Discovery Corporation operates as a subsidiary of Nanosyn Inc.
Nanosys
Series A in 2002
Nanosys, Inc. develops and delivers quantum dot technology for high definition viewing experience for the display industry. It offers Quantum Dot Concentrate material; quantum dot nanomaterials; and Quantum Dot Enhancement film to industrial supply chain partners. Its products are used in tablets, televisions, smartphones, and other consumer electronics applications. Nanosys, Inc. was incorporated in 2001 and is based in Milpitas, California.
Glympse Bio
Series A in 2018
Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis.
Glympse Bio’s platform technology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering.
Interline Therapeutics
Seed Round in 2021
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
It uses genomics, proteomics, structural biology, and computational chemistry to map and modulate protein communities. Interline leverages recent advancements in these technologies, as well as collaborations with leading academic groups, to develop a precision medicine platform focused on three essential areas, genomics, communities, and modulators.
The South San Francisco, California-located company was founded by Zach Sweeney in 2020.
NeurogesX
Series C in 2004
NeurogesX, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel non-opioid, pain management therapies to address unmet medical needs. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is based in San Mateo, California.
Boreal Genomics
Series C in 2013
Boreal Genomics Inc. develops and markets technologies for blood-based detection and monitoring of circulating tumor DNA. It offers OnTarget, a tool for the detection and quantification of tumor mutations in plasma or tissue; Aurora that purifies and concentrates nucleic acids from a range of samples, including life sciences research, soil and environmental, agriculture biotechnology, and forensics. The company was founded in 2007 and is headquartered in Los Altos, California with an additional office in Vancouver, Canada.
Limerick BioPharma
Debt Financing in 2007
Limerick BioPharma is dedicated to developing compounds that, when used adjunctively with both marketed and investigational drugs, significantly improve the quality of patients' lives. Their compounds minimize toxic side effects at non-targeted vulnerable organs and tissue while maintaining or enhancing a drug's desired effects. In the monotherapy setting, they are developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia.
OncoResponse
Series B in 2018
OncoResponse Inc. is an immuno-oncology company that discovers cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system. It develops human antibody derived therapeutics for the treatment of cancer. The company is based in Houston, Texas.
Illumina
Venture Round in 2000
At Illumina, we’re committed to unlocking the power of the genome, and we know we can’t do it alone. Illumina Accelerator is our way of accelerating innovation in the entrepreneurial community. With extensive mentorship, financial support, and access to sequencing systems, reagents, and lab space, we’ve created a dynamic genomic ecosystem to help startups launch. Together we’ll advance the solutions that will transform medicine and improve human health and beyond.
NexCura
Series A in 1999
NexCura applications and custom services are made available through an application service provider (ASP) model on Web sites and are used to collect comprehensive clinical data and facilitate communication between patients and their physicians. The aggregate data They collect provides direct value to healthcare organizations, pharmaceutical companies, physicians, and patients.
Viathan Corporation
Venture Round in 2000
Viathan is focused on the development of software infrastructure for storage environments. It offers a virtual storage system that allows additional storage devices to be aggregated into the environment.
Viathan was acquired by Dantz Development in October 2001.
Viathan was founded in February 1999 and is based in Seattle, Washington.
Impinj, Inc.
Series E in 2007
Impinj is a provider of RAIN RFID solutions that deliver Item Intelligence to retail, pharmaceutical, healthcare, food and beverage, and many other industries. We enable the Internet of Things to identify, locate and authenticate billions of items, and our Item Intelligence platform comprises the most comprehensive and widely adopted RAIN RFID product portfolio in the world. For more information about Impinj, visit www.impinj.com.
Gossamer Bio, Inc.
Series A in 2018
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
Omniome
Series C in 2020
Omniome engages in developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy. Backed by leading life sciences venture investors and a proven management team, Omniome’s vision is to be the most trusted DNA sequencing platform and leader in clinical sequencing.
Founded in 2013, the company is headquartered in San Diego, California, United States.
eGenesis
Series B in 2019
Egenesis Inc., a biotechnology company, operates as a gene editing and genome engineering that develops human transplantable organs, tissues, and cells. It offers a gene editing platform for developing human compatible organs. The company also provides development, such as gene engineering, single cell cloning, somatic cell nuclear/embryo transfer, organ procurement, and transplantation. The company was incorporated in 2015 and is based in Cambridge, Massachusetts with an additional office in New York, New York.
Receptos
Series A in 2009
Receptos is a privately-held drug discovery and development company which utilizes pioneering G protein-coupled receptor (GPCR) technology to facilitate information-driven drug design for developing best- and first-in-class drugs.
Vividion Therapeutics
Series B in 2019
Vividion Therapeutics, Inc., a biotechnology company, develops therapeutics to treat major unmet medical needs using the platform for proteome-wide small molecule drug discovery. The company combines a proteome-wide small molecule screening approach and synthetic chemistry techniques. It provides small molecule selectivity and creates a path to drugging any protein. The company was incorporated in 2013 and is based in San Diego, California.
Amphora Discovery
Series E in 2006
Amphora Discovery Corporation operates as a biotechnology company. It provides integrated services to the pharmaceutical industry. The company's products and services include in vitro assay protocols, in vitro throughput screening and compound profiling services, custom assay development, enzymology services, and lead discovery/lead optimization partnering programs. It offers drug discovery contract research services, HTS, profiling and lead generation, and lead optimization solutions. The company serves pharmaceutical and biopharmaceutical companies, emerging biotechnology companies, and research foundations. Amphora Discovery Corporation was founded in 2001 and is headquartered in Durham, North Carolina. As of July 2008, Amphora Discovery Corporation operates as a subsidiary of Nanosyn Inc.
Nutcracker Therapeutics
Series B in 2020
Nutcracker Therapeutics, Inc. develops mRNA therapeutics to produce mRNA and delivery vehicle formulations on single-use biochips. The company provides a push-button mRNA synthesis and formulation platform. The company was incorporated in 2017 and is based in Emeryville, California.
Brii Biosciences
Venture Round in 2018
Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's medicines focuses on infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients, enabling patients to get access to better treatments and cures for life-threatening diseases.
Hangzhou Just Biotherapeutics (Just China)
Series A in 2016
Hangzhou Just Biotherapeutics, Ltd., also known as Just China, develops antibody and recombinant protein bio-therapeutics. The company was founded in 2016 and is based in Hangzhou, China. Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of Just Biotherapeutics, Inc. As of January 2, 2019, Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of MabSpace Biosciences Co., Ltd..
Hangzhou Just Biotherapeutics (Just China)
Series A in 2015
Hangzhou Just Biotherapeutics, Ltd., also known as Just China, develops antibody and recombinant protein bio-therapeutics. The company was founded in 2016 and is based in Hangzhou, China. Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of Just Biotherapeutics, Inc. As of January 2, 2019, Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of MabSpace Biosciences Co., Ltd..
Limerick BioPharma
Series C in 2009
Limerick BioPharma is dedicated to developing compounds that, when used adjunctively with both marketed and investigational drugs, significantly improve the quality of patients' lives. Their compounds minimize toxic side effects at non-targeted vulnerable organs and tissue while maintaining or enhancing a drug's desired effects. In the monotherapy setting, they are developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia.
ROME Therapeutics, Inc.
Series A in 2020
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.
Ahura Scientific
Series B in 2007
Ahura Scientific Inc. develops rugged, ultra-compact, field-enabled optical systems for the immediate identification and authentication of liquid and solid chemical substances. Customers include agencies and companies in the homeland security, life sciences, industrial and medical markets. Manufactured in the USA in an ISO 9001-certified facility, the company's products offer exceptional portability and unparalleled performance.
Adesto Technologies Corporation
Series A in 2008
Adesto Technologies Corporation, Inc. operates as a silicon valley fabless semiconductor company. The company develops next-generation ultralow-power embedded non-volatile memory technology. Adesto Technologies Corporation, Inc. was founded in 2006 and is based in Sunnyvale, California.
Vividion Therapeutics
Series A in 2017
Vividion Therapeutics, Inc., a biotechnology company, develops therapeutics to treat major unmet medical needs using the platform for proteome-wide small molecule drug discovery. The company combines a proteome-wide small molecule screening approach and synthetic chemistry techniques. It provides small molecule selectivity and creates a path to drugging any protein. The company was incorporated in 2013 and is based in San Diego, California.
Agrivida, Inc.
Series E in 2016
Agrivida, Inc., an animal health and nutrition company, develops feed additives for poultry, swine, dairy and beef cattle, and aquaculture markets. The company offers nutrition solutions for monogastric and ruminant animals, and aquaculture. It offer GRAINZYME, a phytase feed additive for poultry sector. It also provides INzyme Enzymes that deliver regulated enzymes for detergents, oil and gas production, and food applications; and INzyme sugar feedstock advanced bio-based chemical and fuel production. Agrivida, Inc. was founded in 2003 and is based in Four Seasons, Missouri.
Mindstrong Inc.
Series A in 2017
Mindstrong Health develops comprehensive care pathways based on passively-collected, continuous and objective measures of cognitive function and mood. Solutions include a patient-facing app, a provider-facing product, and clinical services that leverage its telehealth enabled measurement science and engagement platform. Mindstrong is partnered with leading organizations committed to advancing medical innovation and improving healthcare delivery for patients, including pharmaceutical companies, large payers and providers, large employers, and state and county governments, in addition to top-tier academic institutions for clinical research.
ApoGen Biotechnologies
Series A in 2016
ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
Crystal IS
Venture Round in 2010
Crystal IS is the market leader in the commercialization of single-crystal aluminum nitride (AlN) substrates for the cost-effective production of long lasting, energy efficient, water and air purification devices.
Elixir Pharmaceuticals
Series D in 2009
Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.
WuXi Nextcode Genomics, Inc.
Series A in 2013
NextCODE Health is a sequence-based clinical diagnostics company delivering a powerful solution to genome interpretation and big data challenges. Using technology developed over more than 16 years at deCODE genetics, we are enabling the widespread incorporation of genome sequence data into patient diagnosis and care.
NextCODE was acquired by WuXi AppTec in 2015 and was renamed WuXi NextCODE before rebranding to [Genuity Science](/organization/genuity-science) in 2020.
Artificial Muscle Inc.
Series A in 2004
Artificial Muscle Inc. is a U.S.-based company that develops polymer components, which convert electrical energy into mechanical motion. It offers electro-magnetic actuators for medical, pumps, sensors, optics, energy generation, valves, Braille, and robotics applications.
Artificial Muscle Inc. is based in Menlo Park, California.
Denali Therapeutics Inc.
Series A in 2015
Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.
Nura
Series A in 2004
Nura, Inc. purpose of discovering and developing pharmaceuticals for the treatment of neurodegenerative diseases, such as Parkinson’s and Alzheimers’s diseases, and behavioral disorders, such as depression, anxiety, schizophrenia, obesity and addiction.
Crystal IS
Series B in 2006
Crystal IS is the market leader in the commercialization of single-crystal aluminum nitride (AlN) substrates for the cost-effective production of long lasting, energy efficient, water and air purification devices.
Sonoma Pharmaceuticals
Series A in 2020
Sonoma Pharmaceuticals is a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 33 countries. The company’s products, over 100 SKUs commercialized worldwide, are used to treat patients in advanced wound management, dermatology, women’s health and animal health; addressing the unmet medical needs of these markets—while raising the standard of patient care and lowering overall healthcare costs.
Metacrine
Series A in 2015
Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.
eGenesis
Series A in 2017
Egenesis Inc., a biotechnology company, operates as a gene editing and genome engineering that develops human transplantable organs, tissues, and cells. It offers a gene editing platform for developing human compatible organs. The company also provides development, such as gene engineering, single cell cloning, somatic cell nuclear/embryo transfer, organ procurement, and transplantation. The company was incorporated in 2015 and is based in Cambridge, Massachusetts with an additional office in New York, New York.
Metacrine
Series B in 2017
Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.
Cambrios Technologies Corporation
Venture Round in 2012
Cambrios Technologies Corp. develops electronic materials for the display industry. The company provides wet-processable transparent conductive films. Its nanostructured materials can be deposited using existing production equipment to achieve enhanced performance of display devices and components. The company was founded in 2002 as Semzyme, Inc. and changed its name to Cambrios Technologies Corp. in August 2004. Cambrios Technologies Corp. is based in Sunnyvale, California.
Syros Pharmaceuticals
Series A in 2013
Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D.
Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
Qihan Biotech
Series A in 2018
Qihan Biotech is a biomedical company based on genetic technology. Kaixin Bio ’s mission is to create a new world where patients do n’t have to wait for organ transplants. We are committed to using the world's advanced gene editing technology to produce safe and effective cells, tissues and organs that can be used for human transplantation, and to solve the serious shortage of organ transplant donors in China and the world.
New Era of Networks
Series C in 1996
New Era Technologies is a U.S.-based R&D technology company. The company develops markets and supports application integration software and provides application integration services.
The company’s main product is NeoNet, software that facilitates the rapid and efficient deployment and ongoing maintenance of application integration across the enterprise.
The company was acquired by Sybase in 2001.
The company was founded in 1995 and is based in Colorado.
Volastra Therapeutics, Inc.
Seed Round in 2021
Volastra Therapeutics, Inc., a biotechnology company, develops therapies for the treatment of metastatic cancers. The company offers a library of organoids derived from metastatic cancer samples to elucidate how tumors spread and devise therapeutic strategies that target chromosomal instability during the process of cancer metastasis. Volastra Therapeutics, Inc. was incorporated in 2019 and is based in New York, New York.
INFICON
Post in 2002
INFICON provides world-class instruments for gas analysis, measurement and control.
INFICON is a provider of innovative instrumentation, critical sensor technologies, and advanced process control software that enhance productivity and quality in sophisticated industrial vacuum processes. These analysis, measurement and control products are essential for gas leak detection in air conditioning/refrigeration and automotive manufacturing. They are vital to equipment manufacturers and end-users in the complex fabrication of semiconductors and thin film coatings for optics, flat panel displays, solar cells and industrial vacuum coating applications. Other users of their vacuum-based processes include the life sciences, research, aerospace, packaging, heat treatment, laser cutting and many other industrial processes. They also leverage their expertise in vacuum technology to provide unique, toxic chemical analysis products for emergency response, security, and environmental health and safety.
INFICON is headquartered in Switzerland and has world-class manufacturing facilities in Europe, the United States and China, as well as subsidiaries in China, Finland, France, Germany, India, Italy, Japan, Korea, Liechtenstein, Singapore, Sweden, Switzerland, Taiwan, the United Kingdom and the United States.
INFICON is ISO 9001 and ISO 14001 registered at their main locations. Many of their instruments are manufactured RoHS compliant.
VBI Vaccines Inc.
Series A in 2007
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
VBI is headquartered in Cambridge, MA with research facilities in Ottawa, Canada.
BIND Therapeutics
Series C in 2010
They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.
Theraclone Sciences, Inc.
Venture Round in 2010
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.
SciNeuro Pharmaceuticals
Series A in 2020
SciNeuro Pharmaceuticals develops medicines for patients with central nervous system (CNS) diseases. The company is based in Shanghai, China.
New Era of Networks
Series B in 1995
New Era Technologies is a U.S.-based R&D technology company. The company develops markets and supports application integration software and provides application integration services.
The company’s main product is NeoNet, software that facilitates the rapid and efficient deployment and ongoing maintenance of application integration across the enterprise.
The company was acquired by Sybase in 2001.
The company was founded in 1995 and is based in Colorado.
Oncofactor Corporation
Series A in 2011
Oncofactor is a Seattle, Washington-based developer of cancer therapeutics that disrupt signaling pathways between tumors and the immune system.
LightCross, Inc.
Series A in 2000
LightCross, Inc develops proprietary technologies that will enable the use of well-developed silicon integrated circuit fabrication equipment and processes to manufacture advanced optical networking components.
Amphora Discovery
Series B in 2004
Amphora Discovery Corporation operates as a biotechnology company. It provides integrated services to the pharmaceutical industry. The company's products and services include in vitro assay protocols, in vitro throughput screening and compound profiling services, custom assay development, enzymology services, and lead discovery/lead optimization partnering programs. It offers drug discovery contract research services, HTS, profiling and lead generation, and lead optimization solutions. The company serves pharmaceutical and biopharmaceutical companies, emerging biotechnology companies, and research foundations. Amphora Discovery Corporation was founded in 2001 and is headquartered in Durham, North Carolina. As of July 2008, Amphora Discovery Corporation operates as a subsidiary of Nanosyn Inc.
Boundless Bio, Inc.
Series A in 2019
Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.
Fast Track
Series D in 2003
Fast Track: a completely new and comprehensive approach to the way clinical trials are managed. The company is assembling a creative and energetic staff of technical and medical professionals, an experienced management team, industry-specific advisory boards, and an active investor constituency - all aggressively focused on achieving their vision: to revolutionize the management of clinical trials.
KOTURA
Series A in 2004
KOTURA, Inc. provides silicon photonics, designs, manufactures and markets CMOS optical components that enable optics to migrate throughout the communications industry. They also provide custom chip design, fabrication, and packaging services.
Elixir Pharmaceuticals
Series C in 2006
Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.
ProjectGuides.com
Series A in 1999
ProjectGuides.com is the premier online marketplace for buyers and sellers of professional services within the architectural, engineering and environmental industries. ProjectGuides.com has pioneered qualifications-based search technology that joins these professionals with public and private buyers.
Backed by a team dedicated to customer satisfaction and success, their system currently tracks professional service opportunities in over 100 industry categories by continuously scanning over 5,000 electronic and print sources. ProjectGuides.com delivers 3,000 leads per week and billions of dollars worth of business opportunities annually to its subscribers, along with industry news and online business tools.
ProjectGuides.com is reinventing how the professional service industry, in the built and natural environment, conducts business. With headquarters in Bellevue, Washington, ProjectGuides.com is a rapidly growing, closely held private company with strategic funding from Alta Partners and ARCH Venture Partners.
Transcenta Holding Ltd.
Series B in 2020
Transcenta Holding Ltd., a biotherapeutics company, engages in the research and development and manufacturing of antibody-based therapeutics. The company also offers clinical researches and trial services. Transcenta Holding Ltd. was founded in 2019 and is based in Suzhou, China. It has additional centers in Shanghai, Hangzhou, and Beijing, China; Waltham, Massachusetts; and Princeton, New Jersey.
Ciespace
Series A in 2010
Ciespace Corporation is an early stage software technology company based in Santa Clara, California, delivering an innovative Software-as-a-Service (SaaS) based computer-aided engineering (CAE) platform for advanced mechanical engineering design and analysis. The Ciespace solution will be the first commercially-available end-to-end CAE solution built entirely on an open, web services platform – leveraging the latest technology developments in cloud computing, high performance distributed networking, and advanced graphics processing – to deliver an entirely new paradigm of engineering design and analysis solutions.
The Ciespace mission is to empower engineers with the critical tools and technology to accelerate innovation in a rapidly-changing, internet-connected global engineering marketplace. Our goal is to provide mid-market manufacturing companies with an open, easily-extendable engineering platform that will allow organizations to more effectively compete on a global basis – enabling improved collaboration, higher product quality, and shorter product design cycles – all delivered through an on-demand variable subscription and usage-based pricing model, to significantly lower the overall cost of digital simulation.
Nitronex
Venture Round in 2006
Specializing in the development and manufacturing of gallium nitride-on-silicon (GaN-on-Si) RF power devices, Nitronex is the global leader in high-performance GaN-on-Si RF power devices.
Nitronex develops and manufactures gallium nitride-on-silicon (GaN-on-Si) RF power devices.
Nitronex was founded in 1999 by graduates of the wide bandgap program at North Carolina State University and is headquartered in Durham, North Carolina. It holds 21 patents with 17 others pending.
Adesto Technologies Corporation
Series D in 2012
Adesto Technologies Corporation, Inc. operates as a silicon valley fabless semiconductor company. The company develops next-generation ultralow-power embedded non-volatile memory technology. Adesto Technologies Corporation, Inc. was founded in 2006 and is based in Sunnyvale, California.
Vir Biotechnology, Inc.
Venture Round in 2017
Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases. The company brings together cutting-edge innovations with scientific expertise and management. It seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions.
Vir Biotechnology also focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Their vision is that one day, diseases like hepatitis B, influenza A, HIV, and tuberculosis become a thing of the past.
Kilimanjaro Energy
Series A in 2010
Kilimanjaro Energy, Inc., a research and development company, engages in the demonstration, commercialization, and promulgation of the air-capture technology for the capture of carbon dioxide (CO2) from the atmosphere. It focuses on the development of ACCESS, an atmospheric carbon capture system. The company was formerly known as Global Research Technologies, LLC. Kilimanjaro Energy was founded in 2004 and is based in Waukesha, Wisconsin with a development and business presence in New York, New York, as well as administrative offices, a research laboratory, and a prototype development and demonstration area in Tucson, Arizona.
Vascular Architects
Series E in 2004
Vascular Architects, Inc. designs, develops, manufactures and markets devices used in the treatment of vascular stenoses, occlusions and non-vascular obstructions. A key area of emphasis is the treatment of peripheral vascular disease, which manifests itself as a reduction or loss of blood flow due to the narrowing or closing of arteries.
Vascular Architects was founded in October 1997 by Thomas J. Fogarty, M.D. Dr Fogarty is an internationally renowned surgeon, professor, inventor and entrepreneur who has founded or cofounded more than 25 start-up companies that develop innovative medical devices. He has authored or coauthored over 150 professional articles, is a member of 29 professional societies, and is an inventor on more than 65 U.S. patents.
Their founder and management team form a highly experienced group of technical, clinical and business personnel. Key opinion leaders in the interventional and vascular surgery communities have been recruited to serve on the Vascular Architects' Scientific Advisory Board.
Fast Track
Series C in 2001
Fast Track: a completely new and comprehensive approach to the way clinical trials are managed. The company is assembling a creative and energetic staff of technical and medical professionals, an experienced management team, industry-specific advisory boards, and an active investor constituency - all aggressively focused on achieving their vision: to revolutionize the management of clinical trials.
Aira Tech Corp.
Seed Round in 2015
Aira Tech Corp. provides an online platform that operates as a visual interpreter and navigator for blind and low-vision users. Its platform enables orientation and mobility experts, such as trained agents, family members, or friends to provide virtual personal assistance by integrating smart glasses with the user's smartphone. The company was formerly known as Kast Inc. Aira Tech Corp. was incorporated in 2015 and is based in La Jolla, California.
908 Devices Inc.
Series D in 2017
908 Devices is bringing the powerful capabilities of Mass Spectrometry out of the confines of centralized facilities and mobile laboratories. The company makes battery-operated, handheld, chemical detection tools, rugged enough to exceed military standards, and trusted enough for immediate action in the field. For biologists and chemists in need of answers, 908 Devices makes personal analyzers, small and simple enough for every workspace.
Grail
Series B in 2017
GRAIL, Inc., a healthcare company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer test to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was founded in 2015 and is headquartered in Menlo Park, California.
Pulmatrix
Series B in 2009
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.
Accelerator Corporation
Venture Round in 2003
Founded in 2003, Accelerator Corporation is a Seattle-headquartered private equity firm with an office in New York and San Diego. The firm is focused on early-stage investments in biotechnology companies.
Ultivue
Series C in 2019
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
It was founded in 2015 and headquartered in Cambridge, Massachusetts.
Acylin Therapeutics
Series A in 2011
Acylin Therapeutics is the first company focused on developing inhibitors of cellular acetylation, an enzymatic mechanism fundamental to the molecular pathology of cancer, metabolic disease, and neurodegeneration. Recent discoveries by Acylin founders and other investigators have revealed protein acetylation as a cellular signal transduction regulator potentially as ubiquitous and important as phosphorylation by kinase enzymes. The Company has developed a platform technology to design specific acyltransferase inhibitors based on crystal structures, novel medicinal chemical approaches, and mechanistic understanding. Acylin has prioritized the p300 and CBP histone acetyl transferases [HATs] for initial drug discovery.
Vizgen, Inc.
Series A in 2020
Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The high throughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms.
Achaogen
Series D in 2013
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.
Innovalight
Series D in 2010
Founded by Conrad Burke, Innovalight is focused on bringing high efficiency, low-cost solar modules to the marketplace. Enabling this manufacturing paradigm shift is the company's silicon ink, which has been in development since 2005. Historically, silicon has been processed either as a solid or as a gas. Using liquid based processing Innovalight will dramatically improve the cost and efficiency of today's solar modules.
Lodo Therapeutics
Series A in 2016
Lodo Therapeutics Corporation is a drug discovery and development company focused on the creation of naturally derived novel therapeutics that will have a dramatic impact human health on a global basis. Lodo seeks to work in partnership with global pharmaceutical companies and world leading Non-Governmental Organizations (NGO’s) to tackle some of the greatest challenges in human health: resistant infectious disease and cancers.
Lodo Therapeutics was created to pursue the scientific vision of Dr. Sean Brady at Rockefeller University. Dr. Brady and his laboratory have developed a genome-based, culture-independent platform for the discovery, biosynthesis, and characterization of small molecules from microbial sources present in soil samples. Lodo believes that the potential cures for a number of deadly and/or debilitating diseases literally lie at our feet. By combining the advancements in DNA sequencing and bioinformatics, this innovative discovery platform exploits the power of microbial evolution for the identification of therapeutically valuable pharmaceutical products derived from natural sources.
Lodo Therapeutics, an Accelerator Corporation-backed entity, is headquartered in New York City. The company’s lab and offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science park.
Reef Point Systems
Venture Round in 2000
As of December 2007, Reef Point Systems, Inc. was acquired by NextPoint Networks, Inc. Reef Point Systems, Inc. provides security solutions for converged wireless and wireline networks in the United States. Its iQ product portfolio enables fixed/mobile convergence security, secure mobile access, network infrastructure protection, and managed security services. It enables operators to secure voice over the Internet protocol, Internet protocol television, and voice, video, and data services from a converged Internet protocol infrastructure. The company’s iQ family lets wireless service providers protect the wireless network infrastructure and deliver multimedia services for mobile users over unlicensed mobile access and Internet protocol multimedia subsystem infrastructure. Its products also enable service providers to offer various security services, including virtual private networks, firewalls, denial of service attack prevention, content filtering, and remote access.
The company, formerly known as Quarry Technologies, Inc., was founded in 1998 and is headquartered in Burlington, Massachusetts.
Arbor Biotechnologies
Series A in 2017
Arbor Biotechnologies operator of a bio-discovery company intended to provide human diagnostic development service. The company's platform employs a diverse set of technologies and techniques including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, enabling drug developers to accelerate the discovery of proteins for improving human health and sustainability.
Theraclone Sciences, Inc.
Series A in 2006
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.
Accelerator Corporation
Venture Round in 2004
Founded in 2003, Accelerator Corporation is a Seattle-headquartered private equity firm with an office in New York and San Diego. The firm is focused on early-stage investments in biotechnology companies.
Cooledge Lighting, Inc.
Series A in 2012
Cooledge Lighting is a venture backed start-up focused on delivering high value solid-state lighting solutions to the general illumination market. Founded in 2009, Cooledge is currently in the development stage of the company with product launch coming at Lightfair 2013 in Philadelphia, PA.
Surface Logix
Series C in 2002
Surface Logix is a drug development company which uses its expertise in biophysical chemistry to create new small molecule drugs with significantly improved pharmacokinetic (PK) and pharmacodynamic (PD) properties compared with class leaders.
bluebird bio, Inc.
Series C in 2011
bluebird bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.
Quanterix
Series D in 2016
Quanterix Corporation is developing a novel platform for single molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. Their unique approach permits rapid quantification and analysis of individual proteins and small molecules within complex biological samples, enabling us to address a variety of unmet medical needs. Founded in 2007, Quanterix is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures.
Voxel8
Series B in 2019
Voxel8 Inc. designs and manufactures electronic devices. It offers desktop 3D printers that are used to print thermoplastics or UV resins. The company also provides Project Wire, a cloud software tool that is used for designing 3D printable electronic devices that can be rapidly fabricated using the Voxel8 3D printer. Voxel8 Inc. was incorporated in 2013 and is based in Somerville, Massachusetts.
Grail
Series A in 2016
GRAIL, Inc., a healthcare company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer test to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was founded in 2015 and is headquartered in Menlo Park, California.
AgBiome, LLC
Series B in 2015
AgBiome, LLC, a biotechnology company, engages in delivering research and discovery to the agriculture industry. The company develops biological product that controls the predominant soil-borne diseases of greenhouse and major row crops. It identifies plant-associated microbes that enhance plant health, pest resistance, and yield applying based on genomics and screening technologies. AgBiome, LLC has strategic partnerships with Genective and ElevateBio. The company was incorporated in 2012 and is based in Durham, North Carolina.
Xenoport
Series B in 2002
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.
MedVantx, Inc.
Series D in 2005
Headquartered in San Diego, California, MedVantx is an innovative consumer medication management and delivery company committed to reducing costs and providing information to benefit patients, healthcare providers, payors, employers and manufacturers.
Their state-of-the-art mail order pharmacy, operating in Sioux Falls, South Dakota, is licensed in all 50 states and serves as a full line mail order prescription drug and information provider to consumers. Their 35,000 square foot facility recently underwent major upgrades and now meets over 200 cGMP-level quality standards and can properly handle all pharmaceuticals requiring Cold Chain processing.
The MedStart Connect program is operational in a number of states including Arizona, California, Florida, Georgia, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island and South Carolina, and serves approximately 4,000 top-decile primary care prescribers. They continue to expand in additional states.
MedVantx was recognized by Inc. Magazine in 2009 as the fastest growing privately held healthcare company in the country and 13th fastest overall.
NeurogesX
Series D in 2005
NeurogesX, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel non-opioid, pain management therapies to address unmet medical needs. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is based in San Mateo, California.
ImmuneID
Venture Round in 2021
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.
Impinj, Inc.
Series B in 2002
Impinj is a provider of RAIN RFID solutions that deliver Item Intelligence to retail, pharmaceutical, healthcare, food and beverage, and many other industries. We enable the Internet of Things to identify, locate and authenticate billions of items, and our Item Intelligence platform comprises the most comprehensive and widely adopted RAIN RFID product portfolio in the world. For more information about Impinj, visit www.impinj.com.
Maze Therapeutics
Series A in 2019
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.and its also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases.
Homology Medicines, Inc.
Series A in 2016
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Magen BioSciences
Series A in 2006
Magen BioSciences is a Biotechnology company located in 100 Beaver Street, Suite 101, Waltham, MA, United States.
Blackthorn Therapeutics, Inc.
Series A in 2016
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.
Univa Corporation
Series B in 2008
Univa is the innovator of workload management solutions that optimize throughput and performance of applications, containers and services. Univa manages workloads automatically by maximizing shared resources and enabling enterprises to scale compute resources across on-premise, hybrid and cloud infrastructures. Univa's solutions help hundreds of companies to manage thousands of applications and run billions of tasks every day to obtain actionable insights and achieve faster time-to-results. Univa is headquartered in Chicago, USA, with offices in Canada and Germany.
Innovalight
Series B in 2006
Founded by Conrad Burke, Innovalight is focused on bringing high efficiency, low-cost solar modules to the marketplace. Enabling this manufacturing paradigm shift is the company's silicon ink, which has been in development since 2005. Historically, silicon has been processed either as a solid or as a gas. Using liquid based processing Innovalight will dramatically improve the cost and efficiency of today's solar modules.
Sapphire Energy, Inc.
Series B in 2008
Sapphire Energy, Inc., a venture capital backed company, produces renewable solutions from algae. It uses sunlight, CO2, non-potable water, non-arable land, nutrients, and novel strains of algae in outdoor ponds to produce biomass that can then be converted into high-value oils, aquaculture and animal feeds, fuels, and other valuable products. The company was founded in 2007 and is based in San Diego, California. It has a research and development facility in Las Cruces, New Mexico; and an integrated algal bio refinery in Columbus, New Mexico.
VentiRx Pharmaceuticals, Inc.
Series B in 2014
VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops and commercializes Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory, and inflammatory diseases. It provides Motolimod, a lead investigational drug to mobilize a patient's own immune system by directly activating myeloid dendritic cells, monocytes, and natural killer cells to fight cancer. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is based in Seattle, Washington. As of February 28, 2017, VentiRx Pharmaceuticals, Inc. operates as a subsidiary of Celgene Corporation.
908 Devices Inc.
Series A in 2012
908 Devices is bringing the powerful capabilities of Mass Spectrometry out of the confines of centralized facilities and mobile laboratories. The company makes battery-operated, handheld, chemical detection tools, rugged enough to exceed military standards, and trusted enough for immediate action in the field. For biologists and chemists in need of answers, 908 Devices makes personal analyzers, small and simple enough for every workspace.
Blackthorn Therapeutics, Inc.
Series B in 2019
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.
Petra Pharma Corporation
Series A in 2016
Petra Pharma Corporation, a pharmaceutical company, discovers and develops therapies that modulate phosphoinositide (PI) signaling pathways for the treatment of cancer and other serious diseases. It focuses on novel enzyme targets that play a central role in various important cellular processes, including cell division, growth, trafficking, and signaling. The company was incorporated in 2015 and is based in New York, New York.
Achaogen
Series C in 2010
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.
LifeMine Therapeutics
Series A in 2017
LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional office in New York, New York.
Ensemble Discovery
Series A in 2004
Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.
Twist Bioscience Corporation
Series C in 2015
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Walden Biosciences
Series A in 2020
Walden Biosciences, Inc, a biotechnology company, develops medicines for individuals living with kidney disease. It targets suPAR, an inflammatory biomarker that connects the kidney to the innate immune system; and Dynamin, a complex enzyme that rebuilds podocytes and the base structure of the kidney. The company was incorporated in 2013 and is based in Cambridge, Massachusetts.
Groove Biopharma
Series A in 2010
Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.
Chiasma
Series C in 2006
Chiasma (Israel) ltd., is a biopharmaceutical company which develops oral drugs based on transient permeability enhancer system. The company offers oral octreotide acetate for the treatment of acromegaly. Its pipeline products include novel drugs which addresses unmet needs for well-defined markets. The company focuses primarily on orphan indications. The company was founded in 2001 and is based in Ness Ziona, Israel. Chiasma (Israel) ltd. operates as a subsidiary of Chiasma, Inc.
Singleron Biotechnology Co.,Ltd.
Series A in 2020
Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.
Shocking Technologies
Series A in 2007
Shocking Technologies, Inc. started operations as a privately held, venture-backed company developing Voltage Switchable Dielectricâ„¢ (VSDâ„¢) materials. A VSDâ„¢ material is a polymer nano-composite that behaves like an insulator (dielectric) during normal circuit operation and becomes conductive when the voltage across the VSDâ„¢ material increases beyond a predefined threshold voltage. The voltage switches back to an insulator again after the voltage drops below the threshold. This unique property, coupled with the ability to tailor the response of the material, opens up several new areas in electronics. The first application being introduced enables embedded electrostatic discharge (ESD) protection in printed circuit boards (PCBs) and semiconductor packages. Subsequent applications will usher in new manufacturing processes as well as novel product designs.
eCustomers.com
Seed Round in 1999
eCustomers, Inc. is revolutionizing the way consumers interact with businesses online. To empower consumers, eCustomers, Inc. was created to be a pioneer and leading Internet-based infomediary that delivers valuable personalized content to eBusiness systems.
Movidius
Series E in 2015
Movidius is a vision processor company that designs compact, high-performance, ultralow power, computational imaging and vision processing chips, software, development tools and reference designs. Movidius’ architecture delivers a new wave of intelligent and contextually aware experiences for consumers in mobile and wearable devices, and other consumer and industrial camera applications.
Movidius is headquartered in San Mateo, California.
Movidius is a venture-backed start-up with investors including: AIB Seed Capital Fund, Atlantic Bridge, Capital-E, DFJ Esprit and Robert Bosch Venture Capital.
Cambrios Technologies Corporation
Series B in 2005
Cambrios Technologies Corp. develops electronic materials for the display industry. The company provides wet-processable transparent conductive films. Its nanostructured materials can be deposited using existing production equipment to achieve enhanced performance of display devices and components. The company was founded in 2002 as Semzyme, Inc. and changed its name to Cambrios Technologies Corp. in August 2004. Cambrios Technologies Corp. is based in Sunnyvale, California.
EQRx
Series A in 2020
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
Limerick BioPharma
Venture Round in 2008
Limerick BioPharma is dedicated to developing compounds that, when used adjunctively with both marketed and investigational drugs, significantly improve the quality of patients' lives. Their compounds minimize toxic side effects at non-targeted vulnerable organs and tissue while maintaining or enhancing a drug's desired effects. In the monotherapy setting, they are developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia.
Groove Biopharma
Series B in 2011
Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.
Semprius
Series B in 2009
Semprius, Inc. engages in the design, development, manufacture, and supply of high concentration photovoltaic (HCPV) solar modules. The company offers its HCPV solar modules to generate solar energy. Its HCPV solar modules serve utility, commercial/industrial, and government/military applications in sunny and dry locations worldwide. The company delivers its products through integrators and EPCs. Semprius, Inc. was formerly known as pSi-tech, Inc. The company was founded in 2005 and is based in Durham, North Carolina.
Karuna Pharmaceuticals
Series A in 2018
Karuna Pharmaceuticals, Inc. engages in development of drugs for the treatment of schizophrenia. The company was incorporated in 2009 and is based in Boston, Massachusetts.
Beam Therapeutics Inc.
Series A in 2018
Over half of the genetic errors associated with disease result from a single-letter change in the billions of bases that form the genome. In other cases, certain natural genetic variations in DNA are known to protect against disease. By changing a single letter – to eliminate errors or write in protective changes – in enough cells, base editing may help us prevent, modify, and even cure a wide range of diseases affecting patients’ lives.
Encoded Therapeutics, Inc.
Series C in 2019
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad range of severe genetic disorders. The company's therapy pipeline addresses devastating genetic and acquired disorders spanning multiple disease pathways including neurocircuitry, metabolic disorders, neurodegeneration and cardiovascular disease, enabling medical practitioners to treat patients and improve their lives.
Trubion Pharmaceuticals
Series B in 2004
Trubion Pharmaceuticals is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. Our product candidates are novel proteins known as single-chain polypeptides and are designed using our SMIPTM custom drug assembly technology.
Univa Corporation
Venture Round in 2011
Univa is the innovator of workload management solutions that optimize throughput and performance of applications, containers and services. Univa manages workloads automatically by maximizing shared resources and enabling enterprises to scale compute resources across on-premise, hybrid and cloud infrastructures. Univa's solutions help hundreds of companies to manage thousands of applications and run billions of tasks every day to obtain actionable insights and achieve faster time-to-results. Univa is headquartered in Chicago, USA, with offices in Canada and Germany.
Geneception
Series A in 2019
Aveso
Series B in 2006
Aveso is the provider of flexible displays suitable for high volume, cost-sensitive mass consumer applications. The company's paper-thin, rugged display products are designed for applications where it has been impossible or impractical to integrate displays in the past, due to cost, form factor or scalability.
Impinj, Inc.
Series A in 2000
Impinj is a provider of RAIN RFID solutions that deliver Item Intelligence to retail, pharmaceutical, healthcare, food and beverage, and many other industries. We enable the Internet of Things to identify, locate and authenticate billions of items, and our Item Intelligence platform comprises the most comprehensive and widely adopted RAIN RFID product portfolio in the world. For more information about Impinj, visit www.impinj.com.
TRELYS
Seed Round in 2013
Trelys, Inc. operates in the biotechnology sector. The company was incorporated in 2012 and is based in San Francisco, California.
Siluria Technologies Inc.
Series B in 2011
Siluria Technologies is a materials innovation company solving global challenges for partners in the natural gas, chemicals and fuel industries. Integrating nanotechnology, biotechnology and chemical engineering, Siluria has developed a solution to the grand challenge of efficient manufacturing: the ability to produce chemicals and fuels from a cheaper, more abundant resource than oil. The company's economically superior, energy-efficient platform converts natural gas into the same materials manufactured today using current industry infrastructure. Siluria's world-class R&D and engineering teams are rapidly commercializing the company's technology to pilot-scale production in close dialogue with the world's largest chemical and fuel companies.Siluria's backers include Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.
Classmates.com
Series B in 2000
Classmates, based in Seattle, Washington, operates the leading online social network service in the United States for bringing high school alumni together. Classmates, which was founded in 1995, serves over 70 million members and enables its users to find and reconnect with high school friends. In addition to facilitating connections with high school friends, Classmates also features the largest library of digitized yearbooks available anywhere on the Internet, with over 300,000 yearbooks available online to help members reconnect, reminisce, engage, and plan reunions with their classmates.
Surface Logix
Series E in 2009
Surface Logix is a drug development company which uses its expertise in biophysical chemistry to create new small molecule drugs with significantly improved pharmacokinetic (PK) and pharmacodynamic (PD) properties compared with class leaders.
Ultivue
Series B in 2018
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
It was founded in 2015 and headquartered in Cambridge, Massachusetts.
Faraday Pharmaceuticals, Inc.
Series A in 2015
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center.
The company was founded in 2014 and is located in Seattle, Washington.
Siluria Technologies Inc.
Series A in 2010
Siluria Technologies is a materials innovation company solving global challenges for partners in the natural gas, chemicals and fuel industries. Integrating nanotechnology, biotechnology and chemical engineering, Siluria has developed a solution to the grand challenge of efficient manufacturing: the ability to produce chemicals and fuels from a cheaper, more abundant resource than oil. The company's economically superior, energy-efficient platform converts natural gas into the same materials manufactured today using current industry infrastructure. Siluria's world-class R&D and engineering teams are rapidly commercializing the company's technology to pilot-scale production in close dialogue with the world's largest chemical and fuel companies.Siluria's backers include Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.
Sienna Biopharmaceuticals, Inc.
Series B in 2017
Sienna Biopharmaceuticals (“sienna”) is a company focused on the discovery, clinical development and commercialization of products in aesthetics and dermatology based on scientific breakthroughs that dramatically improve patient outcomes and physicians’ practice of medicine.
Cero Therapeutics
Series A in 2020
CERo Therapeutics, Inc., a biotechnology company, researches and develops platforms for cellular immunotherapy. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Syros Pharmaceuticals
Series B in 2014
Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D.
Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
Chiasma
Series E in 2015
Chiasma (Israel) ltd., is a biopharmaceutical company which develops oral drugs based on transient permeability enhancer system. The company offers oral octreotide acetate for the treatment of acromegaly. Its pipeline products include novel drugs which addresses unmet needs for well-defined markets. The company focuses primarily on orphan indications. The company was founded in 2001 and is based in Ness Ziona, Israel. Chiasma (Israel) ltd. operates as a subsidiary of Chiasma, Inc.
Impinj, Inc.
Series C in 2004
Impinj is a provider of RAIN RFID solutions that deliver Item Intelligence to retail, pharmaceutical, healthcare, food and beverage, and many other industries. We enable the Internet of Things to identify, locate and authenticate billions of items, and our Item Intelligence platform comprises the most comprehensive and widely adopted RAIN RFID product portfolio in the world. For more information about Impinj, visit www.impinj.com.
Artificial Muscle Inc.
Series B in 2007
Artificial Muscle Inc. is a U.S.-based company that develops polymer components, which convert electrical energy into mechanical motion. It offers electro-magnetic actuators for medical, pumps, sensors, optics, energy generation, valves, Braille, and robotics applications.
Artificial Muscle Inc. is based in Menlo Park, California.
Pulmatrix
Series B in 2011
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.
Newvem
Venture Round in 2012
Newvem is the leader in enhancing cloud usage effectiveness through data analytics.
Newvem’s KnowYourCloud Analytics, a free SaaS solution for Amazon AWS customers, provides a 360-degree view of their cloud usage to enable running a reliable and efficient cloud deployment. The service collects and analyzes AWS usage data, revealing issues and anomalies in their cloud, and recommends actionable insights that help solve not just cost efficiency, but security, availability and utilization issues as well.
Dev-Ops, IT Managers and Business Managers use Newvem everyday to discover meaningful insights on their cloud-based infrastructure, including potential costs savings, security threats, and availability issues. Newvem is led by a seasoned team of serial entrepreneurs and is funded by Greylock Partners, Index Ventures, Innovation Endeavors and others.
VLST Corporation
Series B in 2006
VLST Corporation is a privately held biotechnology company that has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases. The VLST platform uses novel bioinformatics and state-of-the-art proteomics, to identify viral genes whose protein products function as immunomodulatory agents. The resulting product candidates will be either human homologues to these virulence factors or monoclonal antibodies that mimic the function of the virulence gene products. This approach allows for the efficient identification of high quality, pre-validated drug targets for the treatment of autoimmune and inflammatory disorders. The Company's technology has identified potential product candidates for the treatment of disorders such as multiple sclerosis, lupus, psoriasis, rheumatoid arthritis and diabetes.
Semma Therapeutics
Series A in 2015
Semma Therapeutics, Inc. engages in developing a cell therapy for Type 1 diabetes. It focuses on developing a cell therapy for patients who depend on insulin injections. Semma Therapeutics, Inc. has a strategic collaboration with Defymed. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts with an additional office in Boston, Massachusetts. As of October 10, 2019, Semma Therapeutics, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated.
Rodeo Therapeutics Corp.
Series A in 2017
Rodeo Therapeutics Corp. is a drug development company. The company develops novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. It develops drugs for tissue repair and regeneration. The company was incorporated in 2017 and is based in Seattle, Washington.
Ensemble Discovery
Series B in 2007
Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.
Nohla Therapeutics
Series B in 2018
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
KSQ Therapeutics, Inc.
Series B in 2017
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.
ePolicy
Series B in 2000
ePolicy.com Insurance Services, Inc. (ePolicy) is a business-to-business Internet company that is creating a new way for professionals and small businesses to purchase insurance. Backed by some of the world’s leading insurance companies, such as Fireman’s Fund, ePolicy uses the Internet and proprietary technology to streamline the application and policy-writing process. By creating strategic relationships with major insurance companies and by using the efficiencies of the Internet to reduce costs, ePolicy offers a broad range of insurance products to their customers instantly, with high levels of customer service and significantly reduced rates.
ePolicy is distinctly different from other companies currently offering policies on the Internet. Generally, these companies only replicate the offline process by handing customers over to an agent or broker. At ePolicy, they manage the entire customer experience, from getting a quote to printing the policy. Their staff of dedicated customer service representatives are available by phone and on-line to assist with the application and answer questions.
Teach.com
Venture Round in 1999
Teach.com is an all-inclusive educational web resource dedicated to discovering, discussing, and encouraging teaching around the world. It provides current teachers an easy-to-navigate map outlining the steps to become a teacher, including information on teacher salaries, teacher preparation, and certification requirements for all 50 states as well as information on teaching abroad.
It offers current teachers in STEM, and other fields, with the opportunity to receive information about the USC Rossier Online, the top-ranked teacher preparation program delivered online from the University of Southern California.
Teach.com is based in Elk Grove Village, I.L.
Genomics Medicine Ireland
Series A in 2016
Genomics Medicine Ireland is an Irish life sciences company leading a large-scale research study across Ireland looking at the human genome to examine the relationship between genetics, health and disease.
LunaDNA
Venture Round in 2018
Created by co-founders of the $40B DNA sequencing leader Illumina, Luna DNA incentivizes the sharing of health and DNA data for research. LunaDNA rewards people for sharing the data they already own while contributing to medical research and discovery that saves lives.
DNA sequencing data has become siloed. As personal DNA sequencing has risen in popularity, the data has become siloed as each company looks to maximize their individual profit from this data.
There is currently little incentive for consumers to contribute their DNA and health information to a third party database.
There are also multiple privacy, security, and trust issues that limit broad participation.
The solution is LunaDNA.
LunaDNA is a community owned database that rewards individuals shares in the database and rewards for contributing their health and DNA data. Shares entitle members to a share in the profits from medical research and discoveries. The proceeds flow back to the community like dividends as researchers pay to access the data for discovery.
Ahura Scientific
Series B in 2005
Ahura Scientific Inc. develops rugged, ultra-compact, field-enabled optical systems for the immediate identification and authentication of liquid and solid chemical substances. Customers include agencies and companies in the homeland security, life sciences, industrial and medical markets. Manufactured in the USA in an ISO 9001-certified facility, the company's products offer exceptional portability and unparalleled performance.
Sapphire Energy, Inc.
Series C in 2012
Sapphire Energy, Inc., a venture capital backed company, produces renewable solutions from algae. It uses sunlight, CO2, non-potable water, non-arable land, nutrients, and novel strains of algae in outdoor ponds to produce biomass that can then be converted into high-value oils, aquaculture and animal feeds, fuels, and other valuable products. The company was founded in 2007 and is based in San Diego, California. It has a research and development facility in Las Cruces, New Mexico; and an integrated algal bio refinery in Columbus, New Mexico.
Ceptyr
Venture Round in 2002
Ceptyr, Inc was founded to focus on developing drugs against protein tyrosine phosphatases (PTPs), a largely unexplored niche in pharmaceutical development.
Amphora Discovery
Series C in 2004
Amphora Discovery Corporation operates as a biotechnology company. It provides integrated services to the pharmaceutical industry. The company's products and services include in vitro assay protocols, in vitro throughput screening and compound profiling services, custom assay development, enzymology services, and lead discovery/lead optimization partnering programs. It offers drug discovery contract research services, HTS, profiling and lead generation, and lead optimization solutions. The company serves pharmaceutical and biopharmaceutical companies, emerging biotechnology companies, and research foundations. Amphora Discovery Corporation was founded in 2001 and is headquartered in Durham, North Carolina. As of July 2008, Amphora Discovery Corporation operates as a subsidiary of Nanosyn Inc.
LunaDNA
Venture Round in 2019
Created by co-founders of the $40B DNA sequencing leader Illumina, Luna DNA incentivizes the sharing of health and DNA data for research. LunaDNA rewards people for sharing the data they already own while contributing to medical research and discovery that saves lives.
DNA sequencing data has become siloed. As personal DNA sequencing has risen in popularity, the data has become siloed as each company looks to maximize their individual profit from this data.
There is currently little incentive for consumers to contribute their DNA and health information to a third party database.
There are also multiple privacy, security, and trust issues that limit broad participation.
The solution is LunaDNA.
LunaDNA is a community owned database that rewards individuals shares in the database and rewards for contributing their health and DNA data. Shares entitle members to a share in the profits from medical research and discoveries. The proceeds flow back to the community like dividends as researchers pay to access the data for discovery.
Sorbent Therapeutics
Venture Round in 2013
Sorbent Therapeutics, Inc. develops treatment for end stage renal disease patients undergoing dialysis. The company develops fluid retaining polymers for therapeutic uses, such as treatment of kidney diseases. Sorbent Therapeutics, Inc. was founded in 2005 and is based in Vernon Hills, Illinois.
Autobahn Therapeutics
Series B in 2020
Autobahn Therapeutics, Inc. develops small molecule therapies for the treatment of central nervous system (CNS) disorders. The company develops ABX-002, a thyroid hormone receptor beta agonist therapy for the treatment of multiple sclerosis (MS), and adrenomyeloneuropathy (AMN). Autobahn Therapeutics, Inc. was formerly known as Llama Therapeutics, Inc. and changed its name to Autobahn Therapeutics, Inc. in December 2019. The company was incorporated in 2017 and is based in San Diego, California.
Scholar Rock Holding Corporation
Series C in 2018
Scholar Rock, Inc., a biotechnology company, discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.
Unity Biotechnology, Inc.
Series A in 2015
Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.
KSQ Therapeutics, Inc.
Series C in 2018
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.
Ahura Scientific
Series A in 2002
Ahura Scientific Inc. develops rugged, ultra-compact, field-enabled optical systems for the immediate identification and authentication of liquid and solid chemical substances. Customers include agencies and companies in the homeland security, life sciences, industrial and medical markets. Manufactured in the USA in an ISO 9001-certified facility, the company's products offer exceptional portability and unparalleled performance.
Epirium Bio
Series A in 2019
Epirium Bio, Inc. develops compounds for treatment of cardiovascular diseases and metabolic syndrome. Epirium Bio, Inc. was formerly known as Cardero Therapeutics, Inc. The company was incorporated in 2008 and is based in San Diego, California.
Vir Biotechnology, Inc.
Series B in 2019
Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases. The company brings together cutting-edge innovations with scientific expertise and management. It seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions.
Vir Biotechnology also focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Their vision is that one day, diseases like hepatitis B, influenza A, HIV, and tuberculosis become a thing of the past.
Erasca
Series B in 2020
Erasca develops oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations, providing patients with new potential solutions to not just treat but cure cancer.
It was founded in 2018 and headquartered in San Diego, California.
NeurogesX
Series B in 2002
NeurogesX, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel non-opioid, pain management therapies to address unmet medical needs. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is based in San Mateo, California.
Codiak BioSciences, Inc.
Series C in 2017
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
Alfalight
Series B in 2000
Alfalight designs and manufactures high-power diode lasers for the industrial, defense, and telecommunications markets. Alfalight's innovative technology is based on advanced aluminum-free active region (ALFA) laser structures, enabling the manufacture of laser diodes with exceptionally high reliability and industry-leading efficiency.
Aspen Neuroscience
Series A in 2020
Aspen Neuroscience, Inc. develops induced pluripotent stem cells to treat neurological conditions. Its products pipeline includes ANPD001, an autologous neuron replacement therapy in sporadic Parkinson disease; and ANPD002, a gene-edited autologous neuron replacement therapy for familial forms of Parkinson disease. The company was incorporated in 2018 and is based in San Diego, California.
Aira Tech Corp.
Series B in 2017
Aira Tech Corp. provides an online platform that operates as a visual interpreter and navigator for blind and low-vision users. Its platform enables orientation and mobility experts, such as trained agents, family members, or friends to provide virtual personal assistance by integrating smart glasses with the user's smartphone. The company was formerly known as Kast Inc. Aira Tech Corp. was incorporated in 2015 and is based in La Jolla, California.
INFICON
Post in 2003
INFICON provides world-class instruments for gas analysis, measurement and control.
INFICON is a provider of innovative instrumentation, critical sensor technologies, and advanced process control software that enhance productivity and quality in sophisticated industrial vacuum processes. These analysis, measurement and control products are essential for gas leak detection in air conditioning/refrigeration and automotive manufacturing. They are vital to equipment manufacturers and end-users in the complex fabrication of semiconductors and thin film coatings for optics, flat panel displays, solar cells and industrial vacuum coating applications. Other users of their vacuum-based processes include the life sciences, research, aerospace, packaging, heat treatment, laser cutting and many other industrial processes. They also leverage their expertise in vacuum technology to provide unique, toxic chemical analysis products for emergency response, security, and environmental health and safety.
INFICON is headquartered in Switzerland and has world-class manufacturing facilities in Europe, the United States and China, as well as subsidiaries in China, Finland, France, Germany, India, Italy, Japan, Korea, Liechtenstein, Singapore, Sweden, Switzerland, Taiwan, the United Kingdom and the United States.
INFICON is ISO 9001 and ISO 14001 registered at their main locations. Many of their instruments are manufactured RoHS compliant.